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Stratification of colorectal cancer (CRC) into subgroups with different response to therapy was initially 
guided by descriptive associations between specific biomarkers and treatment outcome. Recently, 
preclinical models based on propagatable patient-derived tumor samples have yielded an improved 
understanding of disease biology, which has facilitated the functional validation of correlative 
information and the discovery of novel response determinants, therapeutic targets, and mechanisms of 
tumor adaptation and drug resistance. We review the contribution of patient-derived models to 
advancing CRC characterization, discuss their influence on clinical decision-making, and highlight 






Association studies in patients with CRC have led to the identification of response biomarkers, some of 
which have been implemented as companion diagnostics for therapeutic decisions. By enabling 
biological investigation in a clinically relevant experimental context, patient-derived CRC models have 
proved useful to model the causal role of such biomarkers in dictating drug sensitivity and are providing 
fresh knowledge on new actionable targets, dynamics of tumor evolution and adaptation, and 








Colorectal cancer (CRC) is the third most frequent cause of cancer-related deaths in both the United 
States and Europe (1,2). Around 25% of individuals harbor metastatic disease at the time of diagnosis, 
while approximately 50% of patients will develop metastases later (3). Although 5-year survival rates 
experienced by patients with metastatic CRC (mCRC) remain low (14%) (1), therapeutic options 
developed in the past two decades have prolonged the median overall survival (OS) from 12 to 30 
months (4). This survival advantage can be attributed to improved surgical techniques and the use of 
more effective systemic therapies. At least partially, more informed treatment decisions based on 
molecular response predictors have also helped increase life expectancy, but biomarker recognition has 
been slow and often inconclusive due to the difficulty of substantiating correlative observations in 
patients with functional investigation in clinically relevant model systems. Similarly, while genomic 
datasets have offered an instructive compendium of the genes that are frequently altered in CRC (5), the 
question whether the aberrant protein products of such genes represent effective therapeutic targets 
remains hard to address in the absence of adequate translational tools. 
 
The availability of large collections of patient-derived tumor samples that can be propagated in mice 
(xenografts) and in three-dimensional cultures (organoids) has spearheaded attempts to afford 
biomarker-response associations with mechanistic annotation and has facilitated studies aimed to model 
cancer progression and acquisition of drug resistance (6,7). Herein, we provide an overview of current 
therapies and related biomarkers, as implemented in patients with mCRC, and discuss how patient-
derived xenografts and organoids have been deployed to go beyond correlative descriptions and to 
illuminate fundamental biological and clinical aspects of CRC, including drug repurposing efforts that 
have rapidly moved to the clinical space. Further, we consider the practical implications and the 
limitations of using such models in terms of clinical applicability and predictivity.  
 
 
Empirical and biomarker-driven treatments: Correlative response predictors in patients 
 
The standard-of-care treatment for mCRC patients includes cytotoxic agents and biological targeted 
compounds, which are administered cumulatively based on the empirical observation that multi-agent 
therapeutic cocktails are more effective than monotherapies (8,9). Although some patients receive 
important clinical benefit from these regimens, responses are typically limited to a fraction of 
individuals. The polarized distribution of responsive and non-responsive patients likely derives from the 
genomic and functional heterogeneity of mCRC tumors, which display patient-to-patient molecular 
differences that influence treatment outcome. While the application of ‘omics’ technologies has been 
instrumental to enrich for potential responders to targeted therapies, this has been unsuccessful for 
chemotherapy, in part due to its often incompletely understood and diverse mechanisms of action.  
 
Chemotherapy 
The fluoropyrimidine antimetabolite 5-fluorouracil (5-FU) and leucovorin, a biomodulator that 
enhances 5-FU activity, are most often administered in combination with oxaliplatin, a platinum 
compound endowed with inter- and intra-strand DNA cross-linking activity (FOLFOX) (10), or 
irinotecan, a topoisomerase I inhibitor (FOLFIRI) (11). Other therapeutic options include the 
fluoropyrimidine capecitabine plus oxaliplatin (CAPOX/XELOX) and capecitabine plus irinotecan 
(XELIRI). CAPOX/XELOX has shown analogous efficacy and safety compared to FOLFOX and it is 
typically given as first- or second-line therapy in patients refractory to irinotecan-based chemotherapy 
(12). XELIRI is non-inferior to FOLFIRI in terms of OS and is now recommended as an alternative 
second-line backbone treatment (13). In patients who have progressed after all standard therapies, a 
statistically significant (but modest) improvement in OS can be obtained with TAS-102, an agent that 
combines trifluridine (a nucleoside analog) and tipiracil hydrochloride (an inhibitor of thymidine 
phosphorylase) (14).  
 
Potential determinants of response to chemotherapy have been brought to the fore based on the 
mechanism of action and metabolism of the various agents. However, the application of such predictors 
in clinical practice has been hampered by inconsistent results among different case series and poor 
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diagnostic sensitivity and specificity. For some chemotherapeutics, in consonance with data from 
targeted therapies, drug target overexpression may be a positive determinant of sensitivity. For example, 
high expression of thymidylate synthase (TS), a direct target of 5-FU, has been associated with longer 
survival in CRC patients treated with adjuvant 5-FU-based therapy in some studies (15,16); however, 
other reports have not confirmed the positive predictive value of TS overexpression (17,18) (Table 1). 
Likewise, elevated levels of topoisomerase 1 appear to predict better response to irinotecan (19) (Table 
1). The activity of drug metabolic pathways is also thought to affect chemosensitivity. 
Dihydropyrimidine dehydrogenase (DPD) is a rate-limiting enzyme in fluoropyrimidine catabolism. 
High expression of DPD has been documented in tumors from patients with reduced sensitivity to 
capecitabine (20), with or without irinotecan (21), whereas inactivating polymorphisms of the DYPD 
gene (encoding DPD) have been associated with acute toxicity over the course of fluoropyrimidines-
based therapy (22-24) (Table 1). In the same vein, deleterious polymorphisms of the UGT1A1 gene 
(encoding glucuronosyltransferase, a key enzyme of irinotecan metabolism) are more frequent in 
patients who experience severe toxicity during treatment with irinotecan-based regimens (25,26) (Table 
1). 
 
Responsiveness to chemotherapy may also be related to defects in DNA repair mechanisms after 
chemotherapy-induced DNA damage, leading to abnormalities in DNA replication and/or chromosome 
segregation that culminate in cancer cell death. Excision repair cross-complementation group 1 
(ERCC1) is a key effector of DNA repair mechanisms and influences the tumor DNA-targeting effect 
of oxaliplatin. Some studies have shown that low transcript expression of the ERCC1 gene correlates 
with longer survival of patients treated with FOLFOX (27) (Table 1). Similar findings were reported for 
an ERCC1 polymorphism at codon 118, which is expected to result in decreased ERCC1 gene expression 
(28) (Table 1). These correlations, however, have not been confirmed in other datasets, especially when 
ERCC1 protein amounts rather than transcript expression were analyzed (29,30). Functional studies are 
needed to deepen mechanistic investigation of the relationship between DNA repair deficiency and 
chemosensitization. More in general, we advocate a revamping of biologically oriented research as a 
means to disentangle the intricacies behind chemotherapy efficacy (or lack of), including the evaluation 
of how genetic and epigenetic modifications in components of DNA repair pathways shape response to 
cytotoxic agents. A clearer understanding of the cellular and molecular underpinnings of chemotherapy 
activity in clinically relevant experimental models is a necessary step for the nomination of response 
biomarkers above and beyond descriptive variables in patients. 
 
EGFR monoclonal antibodies 
The EGFR monoclonal antibodies cetuximab and panitumumab are currently used in association with 
FOLXOX or FOLFIRI in the first- or second-line treatment of patients with KRAS or NRAS wild-type 
tumors (31). The restricted use of anti-EGFR antibodies to patients with RAS wild-type mCRC is the 
result of a population-level biomarker-development strategy motivated by the plausible rationale that 
constitutive activation of signaling pathways downstream from EGFR – such as those triggered by RAS 
mutations – should bypass EGFR inhibition and therefore obviate sensitivity to EGFR targeted agents. 
Evidence of the correlation between RAS genetic alterations and lack of response to EGFR blockade 
was initially limited to tumors with exon 2 KRAS mutations (32) and was later extended to KRAS exons 
3 and 4 and NRAS exons 2, 3 and 4 (33) (Table 1). The predictive value of the association was so strong 
that retrospective studies in patients were deemed sufficiently powered to guide the development of 
companion diagnostics for the routine assessment of “RAS extended” mutations in mCRC patients, even 
in the absence of prospective validation.  
 
Although patients with “RAS extended” mutations are currently excluded from therapy with cetuximab 
or panitumumab, there is still some debate as to whether KRAS G13D mutations – different from all 
other RAS mutations – predict some benefit from EGFR antibody treatment. Based on retrospective 
pooled analyses of multiple trials, the addition of cetuximab to first-line or salvage chemotherapy was 
shown to improve the outcome of patients with KRASG13D mutant tumors (with relative treatment effects 
similar to those observed in subjects with KRAS wild-type tumors, but with lower absolute values) 
(34,35). This association was not reproduced in another pooled retrospective evaluation of patients 
treated with panitumumab and chemotherapy (36). Whether this discrepancy is due to the different 
characteristics of the two antibodies (cetuximab is a human-mouse chimeric antibody that contains the 
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human IgG1 constant region, whereas panitumumab is a fully humanized IgG2), or to differences in the 
clinical characteristics of the patient subgroups analyzed, remains to be determined. It is worth noting 
that the longer survival enjoyed by subjects with KRASG13D mutant tumors treated with cetuximab and 
salvage chemotherapy was not observed in the cetuximab monotherapy arm (34), a finding confirmed 
in an independent study in patients who had received single-agent cetuximab (37); hence, the 
confounding effect of the chemotherapy backbone cannot be excluded. The potentially stronger reliance 
of cancer cells with KRAS G13D mutations on the EGFR pathway has received some experimental 
support; specifically, KRASG13D mutant cell lines have been demonstrated to be sensitive to the RAS-
inhibitory activity of the GTPase-activating protein neurofibromin (NF1), which is possibly unleashed 
by EGFR blockade; this dependence of KRASG13D mutant cells on the EGFR-NF1 axis could occur 
either because KRAS G13D proteins are particularly responsive to NF1-stimulated GTP hydrolysis (38) 
or because they are incompetent to curb NF1-dependent inactivation of the wild-type KRAS allele 
product, which thus remains modulatable by upstream EGFR signaling (39). However, most cell lines 
with KRASG13D mutations also harbor NF1 loss-of-function alterations (38), so the proposed regulatory 
circuit is likely to be valid only in restricted model systems that are hardly representative of clinical 
reality. 
 
While the use of RAS mutation panels for the exclusion of mCRC patients who will not benefit from 
anti-EGFR therapy is now commonplace, the quest for positive response predictors has lagged behind. 
EGFR is hardly ever mutated or amplified in CRC, indicating that tumor dependency on the EGFR 
pathway does not have an evident genetic basis. Retrospective correlative studies have documented 
higher tumor expression of the EGFR ligands amphiregulin and epiregulin in patients who respond to 
EGFR antibodies (40,41) (Table 1). Hence, mCRC tumors that are sensitive to EGFR neutralization 
appear to rely on EGFR signals owing to ligand-mediated autocrine or paracrine receptor activation. 
This knowledge has not translated into clinical-grade methods for selection of potential responders due 
to the difficulty of dichotomizing continuous variables, such as transcript or protein expression, into a 
digital cut off for univocal allocation of patients to treatment. 
 
Anti-angiogenic therapy 
The first-line treatment for patients with mCRCs harboring KRAS or NRAS mutations comprises either 
FOLFIRI or FOLFOX plus the anti-VEGF antibody bevacizumab (42,43). Whether the addition of 
VEGF-targeting agents to chemotherapy provides comparable or superior benefit to anti-EGFR 
antibodies in the context of KRAS/NRAS wild-type tumors is still a matter of debate (44). Beyond 
bevacizumab, two other anti-angiogenic drugs have been proved to positively impact on PFS and 
response rates when combined with chemotherapeutic agents in late lines of treatment: aflibercept (an 
anti-VEGF-A, VEGF-B, and placental growth factor) (45) and ramucirumab (an anti-VEGF receptor 2) 
(46). Finally, heavily treated chemorefractory patients can experience slightly longer OS when treated 
with the multikinase inhibitor regorafenib, which also targets pro-angiogenic receptors (47). 
 
At present, there are no validated predictors of response to anti-angiogenic agents (48). Clinical reports 
have shown a correlation between more marked responsiveness to bevacizumab and low baseline levels 
of VEGF-A splice isoforms (49), VEGF-D (50), HGF (51), interleukin-8 (52) or the VEGF-A coreceptor 
neuropilin-1 (53), either in plasma or tumors (Table 1). Germline polymorphisms of VEGF-A (54,55), 
VEGF receptor-1 (56) and inflammation- and endoplasmic reticulum-associated genes (57) also show a 
significant interaction with bevacizumab effectiveness (Table 1). Other potential biomarkers predicting 
bevacizumab therapeutic efficacy include loss of chromosome 18q11.2-q12.1 (58) and, more in general, 
a high degree of chromosomal instability (CIN) (59) (Table 1). In the case of regorafenib, initial studies 
suggest that low expression of vascular cell adhesion protein 1 (VCAM-1) may be associated with better 
response (60) (Table 1). Polymorphisms of genes related to the C-C motif chemokine ligand 5/C-C motif 
chemokine receptor 5 pathway (which regulates VEGF-A expression) also predict efficacy in mCRC 
patients treated with regorafenib (61) (Table 1).  
 
The fact that the expression levels of angiogenic targets positively associate with sensitivity to anti-
angiogenic agents has a pharmacokinetic basis ascribable to the relative stoichiometry of drug-target 
interactions. The biological significance of other candidate biomarkers, such as copy number alterations, 
is of difficult interpretation in the absence of functional modeling in adequate experimental systems. 
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Mechanistic investigation of stromal-directed therapies is complicated by a dearth of preclinical 
resources, which typically consist of syngeneic transplants, genetically modified mice, or xenografts. 
All approaches have limitations: on the one hand, “mouse-only” models hardly recapitulate the inter-
patient heterogeneity and population diversity of human tumors – a severe drawback for biomarker 
discovery research; on the other hand, xenografts are by definition a chimeric source of angiogenic 
factors, which can be concomitantly released by human cells of the tumor and murine stromal and 
inflammatory cells of the host. Therefore, due to species specificity, the cross-talk between heterologous 
cellular compartments is biased, and therapeutic antibodies cannot have full capacity at the organismal 
level because they selectively target either murine or human antigens.  
 
Other targeted therapies 
All the above therapies are administered in the absence of positive molecular selection; the only criterion 
is patient exclusion based on the presence of negative response biomarkers, as epitomized by the 
established association between KRAS/NRAS mutations and lack of response to EGFR blockade. 
Recently, a number of low-frequency aberrations in kinase-encoding genes have been identified in 
mCRC that result in constitutive activation of the corresponding protein products. Alterations in the 
ERRB2 gene (mostly gene amplification) are detected in around 5% of KRAS, NRAS or BRAF wild-type 
mCRCs and lead to overexpression and hyperactivation of the encoded HER2 tyrosine kinase receptor. 
Phase 2 studies in patients selected for having HER2-positive mCRC tumors have shown that dual 
inhibition of HER2 using the anti-HER2 antibody trastuzumab and the EGFR/HER2 small-molecule 
inhibitor lapatinib (HERACLES trial) or the combination of trastuzumab and the anti-HER2 antibody 
pertuzumab (MyPathway trial) have considerable clinical efficacy, with around 30% response rates in 
heavily pretreated patients (62,63) (Table 1). Notably, in both studies responsive patients had tumors 
with higher ERBB2 gene copy number than resistant patients, consistent with the assumption that higher 
ERBB2 gene dosage translates into stronger kinase activation, hence in more profound tumor 
dependency on HER2 signaling.  
 
Kinase fusions originating from chromosomal translocations and resulting in constitutive activation of 
neurotrophic receptor tyrosine kinase 1 (NTRK1), NTRK2, NTRK3, anaplastic lymphoma kinase 
(ALK), and RET account for approximately 1-2% of KRAS, NRAS or BRAF wild-type mCRCs. These 
rearrangements are enriched in right-sided RAS wild-type tumors and, while typically portending a 
dismal prognosis (64), they predict therapeutic benefit of inhibitors such as entrectinib (targeting NTRK, 
ROS1 and ALK) (65,66) and ponatinib (targeting various tyrosine kinases including RET) (67,68) 
(Table 1). 
 
BRAF gene alterations (with a dominant prevalence of V600E activating mutations) are found in 7-10% 
of mCRCs (69,70) and are generally mutually exclusive with KRAS and NRAS mutations, indicating that 
a single oncogenic hit on the ERK MAPK pathway is sufficient to sustain tumorigenicity. Selective 
BRAF targeting with specific inhibitors has proven ineffective in patients with BRAF mutant mCRC 
due to feedback reactivation of EGFR signaling, which substitutes for BRAF blockade in stimulating 
the MAPK pathway (71,72). This observation has prompted the design of clinical trials aimed at 
evaluating the efficacy of combined BRAF and EGFR inhibition in patients with BRAF mutant mCRC. 
In a recent phase 3 study testing cetuximab and the BRAF inhibitor encorafenib versus cetuximab and 
irinotecan (or FOLFIRI), combined EGFR and BRAF blockade significantly improved response rates 
and OS compared with standard therapy. This superior activity was further enhanced by concomitant 
MEK inhibition (73) (Table 1). 
 
Despite their high prevalence (approximately 50% of all CRCs), KRAS and NRAS mutant tumors are 
still treated with conventional chemotherapy and anti-angiogenic agents. Hopes are now placed on the 
use of KRAS G12C covalent inhibitors, which are currently tested in patients with KRASG12C solid 
tumors. Initial results seem to indicate that response rates to these drugs are relatively high in patients 
with non-small cell lung cancer but limited in mCRC patients, likely due to retained sensitivity of CRC 
tumors to upstream EGFR signaling (74) (Table 1). These observations echo findings in BRAF mutant 
tumors (71,72) and strengthen the notion that EGFR signaling needs to be concomitantly neutralized to 





About 15% of CRCs display defective functionality of mismatch repair (MMR) proteins, which 
participate in the correction of base-pair mismatches occurring during DNA replication (especially at 
the level of repetitive DNA sequences called microsatellites). Deficient-MRR (dMMR) tumors with 
mutations in 30% or more microsatellites (defined as dMMR/MSI-H, i.e. with high microsatellite 
instability) tend to accumulate nonsynonymous mutations; this increased mutational burden can 
translate into a higher neoantigen load, which makes some dMMR/MSI-H tumors immunogenic and 
sensitive to immune checkpoint blockade (75). Accordingly, single-agent therapy with the anti-PD-1 
antibodies pembrolizumab or nivolumab and combination therapy with nivolumab and the anti-CTLA-
4 antibody ipilimumab have been approved for treatment of patients with chemorefractory dMMR/MSI-
H mCRC (76-78) (Table 1Preclinical evidence also suggests that anti-PD-1 immunotherapy may 
complement the activity of KRAS G12C covalent inhibitors. In a CRC syngeneic mouse xenograft 
model dependent on the KrasG12C allele, KRAS G12C blockade resulted in increased infiltration of CD8+ 
cytotoxic T cells, macrophages, and dendritic cells (79). This pro-inflammatory phenotype sensitized 
tumors to immunotherapy: when combined with an anti-PD-1 antibody, the KRAS G12C inhibitor 
induced complete tumor regressions that persisted also after treatment discontinuation. Interestingly, 
mice that were “cured” by the combined treatment against KRAS G12C and PD-1 rejected tumor 
rechallenge, indicating that the combination therapy favored the establishment of tumor-specific T cell 
responses (79). 
 
The assessment of MSI status is now routinely performed for selecting patients likely to respond to 
immunotherapy, but only a subgroup of individuals with MSI mCRC receive clinical benefit from this 
treatment. Not always are the protein products of somatic DNA variants efficiently presented by MHC 
molecules, which means that tumor mutational burden only partially contributes to neoantigen load. 
Likewise, although an association between high neoantigen load and pronounced immune cell 
infiltration has been repeatedly documented, the presence of an active immune microenvironment has 
not predictive value for immunotherapy sensitivity (80). HLA binding prediction tools and artificial 
intelligence algorithms for multiparametric imaging of immune cell representation and topography in 
tumors are expected to yield more reliable molecular biomarkers for effective patient stratification in 
the immuno-oncology space. 
 
 
Preclinical models for understanding and predicting therapeutic response in CRC 
 
Biomarkers that predict patient response to treatment are usually identified using population-based 
association studies, in which clinical outcome is correlated with a statistically significant enrichment for 
a specific molecular trait (typically, a genetic alteration) in subjects who do or do not respond to a given 
therapy. Albeit useful for clinical decision making, this approach fails to inform whether therapeutically 
relevant response predictors causally influence drug sensitivity and does not provide insight into the 
mechanistic underpinnings of the observed correlations. In a complementary perspective, studies using 
cancer cell lines enable extracting functional annotations and modeling cause-effect relationships; 
however, cell lines are by definition limited in number; thus, they do not recapitulate the spectrum of 
genetic heterogeneity spanned by patient tumors. Recently, patient-derived platforms that reflect the 
diversity of cancers, while retaining experimental manipulability and clinical fidelity, have been 
developed with the aim to characterize response biomarkers, investigate tumor adaptation under drug 
pressure, and understand the evolutionary principles of tumor progression. CRC has been – and still is - 
a testing arena for such efforts. 
 
Patient-derived xenografts (PDXs) for validation of targeted therapy biomarkers 
Surgically derived tumor samples that are implanted in mice (known as patient-derived xenografts, 
PDXs) retain the inherent features of different tumors from different patients (6,81). Vast PDX 
collections are therefore expected to capture inter-patient tumor heterogeneity at the population level in 
a clinically relevant in vivo setting (82). CRC is a paradigmatic example of the importance of PDX-
based research for large-scale genotype-response associations, predictive biomarker identification, and 
therapeutic studies (83,84) (Figure 1). In 2011 a systematic survey of KRAS and NRAS mutations in 
more than 100 PDXs from metastatic CRC tumors, coupled with annotation of sensitivity to cetuximab, 
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produced a dataset with both confirmatory and discovery aspects (85). On the one hand, the association 
between KRAS mutations in exon 2 and de novo resistance to EGFR blockade – which had emerged 
from clinical studies some years earlier (32, 86) – was “reverse validated” in PDXs and found to be 
coherent with patient data (85) (Table 1). On the other hand, results in PDXs were among the first to 
illustrate that KRAS mutations in exons 3 and 4 and NRAS mutations predict lack of response to EGFR 
antibodies (85,87). This finding would receive ultimate clinical recognition only two years later, when 
a retrospective-prospective analysis concluded that patients with tumors harboring “RAS extended” 
mutations treated with anti-EGFR antibodies had inferior PFS and OS compared with patients with 
KRAS/NRAS wild-type tumors (33).  
 
While PDXs appear to have adequate predictive power for cancer cell-directed treatments, they lose 
value when dealing with therapies against stromal components – such as cancer-associated fibroblasts, 
endothelial cells, and inflammatory cells – and cells of the adaptive immune system. Indeed, the host 
must be immunocompromised to tolerate the graft, and human stromal cells are substituted with murine 
counterparts over serial passaging (6). But this drawback bears some advantages: the chimeric nature of 
PDXs has been leveraged to decompose – from bulk tumors – cancer cell-specific and stromal signals 
using analytical methods that distinguish human versus mouse transcripts. This exercise has increased 
the granularity and informative merit of gene expression classifications. For example, the clinical 
aggressiveness of a poor-prognosis transcriptional subtype named CMS4 had been initially ascribed to 
the ability of cancer cells to undergo epithelial-mesenchymal transition (EMT), a phenotypic switch that 
instigates cell motility and invasion (8,88). With the possibility to discriminate between human and 
mouse transcripts, it became clear that – together with displaying some cancer cell-autonomous EMT 
traits – the vast majority of mesenchymal CMS4 tumors are in fact characterized by a heavy content of 
stromal cells, which likely foster the malignant characteristics of this subtype by conveying mitogenic, 
pro-invasive and anti-apoptotic cues (89). In the same vein, CRIS, a new CRC classification based only 
on PDX human transcripts, identified subtypes endowed with prognostic and predictive significance and 
showing limited overlap with transcriptional classes obtained from whole bulk CRCs (90). Moreover, 
by focusing on cancer-cell intrinsic gene expression features that are not influenced by stromal 
abundance in isolated, randomly taken tumor samples, CRIS demonstrated higher accuracy in clustering 
CRCs by patient-of-origin rather than tumor region-of-origin (91). 
 
PDXs to study the clonal dynamics of CRC tumors under chemotherapy pressure 
Tumors are composed of heterogeneous cell subsets that display different proliferation kinetics, 
susceptibility to apoptosis, and sensitivity to drug insults (92). Some works have used PDX models to 
investigate the clonal propagation dynamics of CRC subpopulations, both during spontaneous tumor 
growth and under drug pressure (Figure 1). DNA copy number alteration profiling and deep sequencing 
of mutational hotspots were combined with lentiviral lineage tracking to follow the progeny of single 
CRC cells over serial xenografts and to interrogate the relative contribution of genetic and nongenetic 
mechanisms to the functional heterogeneity of the individual cancer cells (93). While genetically 
identical clones remained stable upon serial transplantation, lentivirally marked lineages were variable 
within each clone, with pronounced differences in proliferation rates, ability to persist, and susceptibility 
to exhaust through passages (93). Likewise, treatment of xenografts with oxaliplatin did not result in a 
detectable bottleneck or selection for novel genetic clones; rather, chemotherapy shaped a new 
dominance of previously dormant lineages and culled actively proliferating progeny (93). Together, 
these results indicate that cancer cells subpopulations can be genetically homogeneous (and stable) but 
functionally heterogeneous (and plastic) in CRC. 
 
The finding that CRC cancer cells oscillate between periods of dormancy and activity appears to have a 
positional determination. Using a tamoxifen-inducible labeling system to stochastically mark cancer 
cells in mouse xenografts of patient-derived spheroids, coupled with computational modeling, Lenos 
and colleagues documented that CRC grows through surface expansion (94). This peripheral accretion 
is driven by the local availability of mitogenic gradients secreted by cancer-associated fibroblasts, which 
are sensed only by cancer cells located in the outermost zone of the tumor (94) (Figure 1). Chemotherapy 
with 5-FU and oxaliplatin reduced tumor growth rates but did not affect the residual dynamics of surface 
growth, indicating that microenvironmental influences dictating spatially confined cell proliferation are 
not interfered by cytotoxic treatment (94). Other studies with multicolor lineage tracing approaches in 
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xenografts of CRC primary cultures and cell lines confirmed that tumor outgrowth is geometrically 
orchestrated by large proliferating clones confined at the leading tumor edge, whilst small quiescent 
clones reside in the center (95,96). 
 
PDXs and genetically modified animal models for target discovery  
Besides providing preclinical hints for response biomarker validation, PDXs have also been deployed 
for testing therapeutic options in newly identified, molecularly circumscribed mCRC subsets (Figure 1). 
Amplification of the ERBB2 oncogene was detected in some KRAS/NRAS wild-type, cetuximab-
resistant PDX models, and was found to predict response to HER2 targeted therapies in PDX-based 
preclinical trials (85,97) (Table 1). Other clinically actionable alterations were shown to be enriched in 
KRAS/NRAS wild-type, cetuximab-refractory PDXs and patients, including activating mutations of 
ERBB2 and MAP2K1 (encoding the RAS downstream effector MEK1), amplification of the tyrosine 
kinase receptors MET and FGFR1, and outlier overexpression of the survival factor IGF2 (98-101). In 
general, the sole inhibition of the hyperactive oncoproteins proved to be ineffective in PDXs, but treated 
tumors were invariably sensitized to concomitant EGFR blockade. Subsequent clinical studies 
confirmed that patients with HER2-positive mCRC tend to respond poorly to EGFR antibodies and can 
benefit from dual treatments against HER2 and EGFR (62,63). Similarly, MEK1 mutations were found 
to predict resistance to EGFR inhibition and response to a combination of trametinib (a MEK inhibitor) 
and panitumumab in patients (102). 
 
PDXs have been shown to recapitulate clinical reality also in terms of depth of response. Similar to 
metastases in patients, mCRC PDXs that respond to EGFR antibodies can experience massive shrinkage 
but are hardly ever eradicated. The residual cancer cells that withstand upfront drug treatments act as a 
reservoir for the stochastic acquisition of resistance-conferring mutations, with the ensuing expansion 
of subclones responsible for tumor relapse (103). Recent evidence indicates that residual mCRC PDXs 
(and residual tumors in patients) at maximal response to prolonged anti-EGFR therapy relax their 
dependency on EGFR signals by reducing the expression of genes encoding EGFR-activating ligands 
and increasing alternate HER2/HER3 pathway activity, while becoming similar to slowly-cycling 
secretory precursors of the normal intestine (104). The finding that cetuximab-tolerant residual tumors 
exhibit decreased abundance of EGFR cognate ligands is consistent with the clinical observation that 
patients with mCRC tumors expressing low levels of amphiregulin and epiregulin tend to respond less 
to EGFR antibodies (40,41) (Table 1). Pseudodifferentiation into tissue-specific lineages has been 
documented as a mechanism of therapy resistance in other tumors; for example, the manifestation of 
neuroendocrine traits is a hallmark of emerging resistance to EGFR inhibitors and anti-androgen 
treatment in lung and prostate cancer, respectively (105,106). In the context of CRC, cetuximab-induced 
phenotypic reprogramming towards a secretory fate with high HER2/HER3 signaling makes cancer cells 
vulnerable to concomitant targeting of EGFR, HER2 and HER3, as shown by reduction of residual 
disease burden and prolonged time to relapse after treatment discontinuation in PDX trials with a Pan-
HER antibody (104). 
 
As noted above, PDXs are inadequate tools for predicting response to therapies against stromal and 
immune cells. Genetically modified mouse models (GEMMs) develop autochthonous CRC tumors in 
an immune-competent background, but the artificial introduction of founder oncogenic mutations may 
result in evolutionary trajectories different from those occurring in spontaneous tumors (107). This 
limitation has been addressed by engineering the ordered expression of salient mutant oncoproteins 
along the linear progression sequence that typifies human CRC, with the aim to more faithfully 
recapitulate the natural history of human tumors. In seminal experiments, individual inactivation of the 
Apc gene (which normally represses intestinal stem cell proliferation by blocking mitogenic signals of 
the Wnt pathway) caused the formation of adenomas and in situ carcinomas (108). In the context of Apc 
deficiency, the concomitant expression of oncogenic Kras or the concomitant loss of the tumor-
suppressor gene Trp53 or the Smad2/Smad4 genes (the latter being downstream mediators of TGF 
signaling) accelerated intestinal tumorigenesis and resulted in the development of locally invasive (albeit 
not metastatic) carcinomas (109-112). Ultimately, the compound assortment of mutations in Apc, Kras, 
and Trp53 or Apc, Kras and Tgfbr2 (encoding the type-2 TGF receptor) enabled implementation of the 
full metastatic phenotype (113,114). Likewise, animals with targeted gene recombination of Apc, Kras, 
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Tgfbr2, and Trp53 (AKTP) to intestinal stem cells developed invasive CRC adenocarcinomas with 
hallmarks of human microsatellite-stable tumors, including low mutational burden and scant T-cell 
infiltration (115). Moreover, AKTP tumors had an abundant representation of carcinoma-associated 
fibroblasts engaged in massive deposition of extracellular matrix and profuse secretion of TGF-. 
Importantly, increased TGFβ in the tumor microenvironment was found to be a major determinant of T-
cell exclusion, and blockade of TGFβ signaling rendered tumors more T cell-inflamed and susceptible 
to immunotherapy (115) (Figure 2). Another mouse model harboring Kras and Trp53 mutations along 
with hyperactive Notch signaling in intestinal cells developed metastatic tumors with serrated 
morphology, extensive stromal content, and gene expression profiles similar to those of poor-prognosis 
tumors in patients (116). In these mouse tumors, hyperactivation of the Notch pathway resulted in 
secretion of TGF- by cancer cells, which prompted neutrophil accumulation in the tumor stroma and 
neutrophil-dependent metastatic dissemination. Accordingly, targeting neutrophil recruitment or TGF-
β signaling reduced metastatic burden (116) (Figure 2). Collectively, these results underscore the value 
of transgenic mice as investigational models to explore the interplay between genetic alterations and the 
immune-competent tumor microenvironment and to integrate PDX-based research on cancer cell-
intrinsic vulnerabilities. 
 
Patient-derived organoids for mechanistic investigation and pharmacologic studies  
PDXs represent more authentic working models than conventional cell-line xenografts to study how 
cancer cells evolve and react to therapies in a clinically relevant scenario that reflects organismal 
complexity. However, PDXs are not endowed with sufficient experimental tractability to distill causality 
from description, nor do they show sufficient scalability to enable high-throughput pharmacogenomic 
screens. Short-term culture of tumor sections allows for in vitro screening at a reasonably large scale 
(117), but it is constrained by the fact that the proliferative capacity of the cultures dissipates over time. 
To overcome these limitations, three-dimensional organotypic or “organoid” long-term culture methods 
have been developed that combine the architectural complexity of tissues with the experimental 
flexibility of “immortalized” cell-culture systems (118). For colon, normal organoids containing only 
epithelial cells can be derived by culturing primary nontransformed intestinal tissue in Matrigel – a 
gelatinous mixture made of laminin-rich extracellular matrix and growth factors – supplemented with 
additional growth factors that mimic the intestinal niche (119,120) (Figure 3). CRC organoids require 
less stringent combinations of niche factors than normal intestinal organoids (121,122). Mouse and 
human organoids are commonly used not only for biological and pharmacologic studies in vitro but also 
as model tools of CRC spontaneous metastatization. GEMM-derived organoids, normal mouse 
organoids engineered to express oncogenic mutations, and patient-derived human tumor organoids can 
readily give rise to invasive carcinomas that infiltrate the muscularis propria and colonize the liver after 
orthotopic engraftment by colonoscopy-guided mucosal injection, enema, or surgical implantation into 
the submucosa of the caecal wall (123-127). 
 
Patient-derived normal and CRC organoids have been leveraged to advance cancer modeling and 
decompose mechanisms of CRC tumorigenesis. Using CRISPR/Cas9-based genome editing, Matano et 
al. sequentially introduced loss-of-function mutations of APC, SMAD4 and TP53 and gain-of-function 
mutations of KRAS and/or PIK3CA in normal human colon organoids, followed by growth selection 
under customized cell culture conditions (128). Organoids engineered to express all five mutations 
formed small, highly differentiated tumors with limited local infiltration after implantation under the 
kidney subcapsule in mice, and were unable to metastasize to the liver after injection into the spleen. 
Conversely, organoids from patients’ advanced tumors that had accumulated spontaneous oncogenic 
mutations during their evolutionary history displayed robust renal subcapsular growth and produced 
prominent spleen-to-liver dissemination (128) (Figure 3). These results suggest that the ectopic 
introduction of canonical driver mutations in normal human intestinal cells results in incipient tumor 
formation but is not sufficient for a CRC tumor to exhibit an invasive and metastatic behavior. 
Additional lesions that drive full-blown CRC malignancy may be fueled by epigenetic modifications 
and CIN; indeed, the engineered organoids largely lacked karyotypic or DNA methylation aberrations, 
which were instead abundantly present in patient-derived CRC organoids (128). The acquisition of gene 
copy number alterations after genetic manipulation of normal intestinal organoids appears to be 
influenced by experimental variables; for example, different from Matano et al., Drost et al. found that 
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combined loss of APC and TP53 in normal human colon organoids was sufficient for the appearance of 
CIN and massive aneuploidy (129). In patient-derived CRC organoids, a combination of genetic lineage 
tracing and ablation systems revealed robust functional plasticity. LGR5+ cells were shown to act as 
cancer stem cells that constantly fueled tumor growth through self-renewal and at the same time were 
able to morph into differentiated post-mitotic cells. Selective ablation of LGR5+ cells transiently 
regressed tumors; however, this shrinkage was followed by tumor regrowth due to the replenishment of 
the LGR5+ pool by differentiated cells that had reacquired stem-like features (130). 
 
Clonal organoids derived from isolated cells can be considered as proxies for the single cells from which 
they originate (Figure 3). Phylogenetic trees constructed through deep genomic analysis of CRC clonal 
organoids revealed that driver mutations commonly found in CRC (such as those in APC, KRAS, and 
TP53) were present in all organoids, that is, they were trunk mutations common to all cells of the original 
tumor. However, many “private” mutations could be detected in the distal branches of the phylogenetic 
trees, indicating that they had arisen later during tumor progression and had contributed to tumor genetic 
diversification (131). These results are in line with the “big bang” model of CRC tumorigenesis, 
according to which genetic variants that confer selective advantages occur early in a cancer’s evolution 
and are followed by the neutral expansion of genetically different but equally fit subclones (132,133). 
Stable alterations of DNA methylation and transcriptome states were also observed in clonal organoids, 
with phylogenetic topologies similar to the mutation-based trees (Figure 3). Conversely, response to 
drugs commonly used in CRC was variable – especially with chemotherapeutic agents – and not linked 
to the geographical location of the organoid-initiating cells in the original tumor or the genetic distance 
between clones (131). Similar to that observed in PDX-based lineage tracking experiments (93), these 
results suggest that diversification in biological behavior has no evident correlation with the extent of 
mutational diversification. 
 
The application of organoid technology in systematic high-throughput drug screens to validate clinically 
relevant response biomarkers and nominate new ones is rapidly expanding (Figure 3). A seminal study 
with a library of 83 compounds tested in 19 organoids from primary CRC tumors confirmed the 
association between KRAS mutations and lack of response to EGFR blockade as well as general 
refractoriness of BRAF mutant tumors to BRAF inhibitors, as observed in the clinic (121). This effort 
also identified loss-of-function mutations in RNF43, resulting in cell hypersensitivity to secreted WNT 
factors, as predictive biomarkers of CRC susceptibility to neutralization of autocrine/paracrine 
activation of the WNT pathway (121). Organoids from metastatic samples have been shown to 
recapitulate the clinical response of the donor patient to cetuximab, regorafenib, and TAS-102 (134). 
Interestingly, organoids derived from a patient with regorafenib-sensitive liver metastases proved to be 
resistant to the drug when cultured ex vivo as isolated cancer cells; however, liver orthotopic xenografts 
developed from the same organoids coopted the host’s blood vessels and displayed reduced vascularity 
after regorafenib administration, in keeping with the assumption that response to regorafenib is mainly 
driven by its antiangiogenic activity (134). A concordance between cancer cell viability and patient 
response was also found in organoids from metastatic tumors treated with irinotecan monotherapy or 
FOLFIRI, but not when FOLFOX was used (135). Possibly, stromal and immune components absent in 
organoid cultures tune sensitivity to oxaliplatin more than they do with other drugs, or reliable response 
to oxaliplatin requires tailored culture conditions that are less stringent for other chemotherapeutics. 
Finally, organoids derived from primary rectal cancers have been demonstrated to predict clinical and 




Challenges and emerging opportunities 
 
The utilization of living biobanks of tumor samples holds considerable promise for in vivo and in vitro 
interrogation of clinically actionable pathways and for the study of tumor evolution. But the use of 
patient-derived models should be accompanied by careful appreciation of their real potential not only as 
platforms for biomarker validation and target discovery but also as reliable proxies of the biological and 
molecular fingerprints of matched tumors in donor patients. A critical knowledge of the accuracy of 
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patient-derived models in retaining the characteristics of original tumors is crucial for assessing their 
ability to predict drug activity in the clinic. 
 
Preservation of genomic architecture in propagated tumor-derived models 
An ongoing debate revolves around the question whether serially passaged PDXs and long-cultured 
organoids preserve the genomic makeup, in terms of copy number alterations (CNAs), of their pre-
derivation counterparts. Using gene expression microarray data to infer large-scale CNA profiles, Ben-
David et al. reported extensive copy number divergence between the pre-implantation tumor of origin 
and the corresponding xenograft at the first in vivo passage, which was exacerbated along serial 
propagations (138). This raised concerns that mouse-specific selective pressures may “artificially” 
influence PDX tumor evolution, with implications for the ability of PDXs to faithfully model patient 
treatment response. However, expression-based CNA calling only enables assessment of aberrations at 
the gross scale of chromosomal arms. Recently, a joint effort of the National Cancer Institute PDXNet 
consortium and the EurOPDX consortium produced a DNA-based enumeration of copy number profiles 
at high segmental resolution in a large collection of PDX models (139). This analysis did not confirm 
systematic copy number deviation between patient tumors and PDXs; rather, it documented high CNA 
retention during PDX engraftment and passaging (both globally and at the level of cancer-related genes) 
for many tumor types including mCRC. Notably, CNA variations between pre-implantation and 
xenografted tumors were comparable to differences in multi-region samples of tumors in patients, 
indicating that the impact of PDX-associated CNA drift is similar to the natural intratumoral evolution 
that occurs in patients.  
 
Somatic mutations, typically assessed by whole exome sequencing, are largely concordant between 
original tumors and matched PDXs, even though evolutionary neutral subclonal alterations may arise at 
low allele frequency during PDX propagation (140). In CRC, mutations in known oncogenic drivers are 
retained in PDXs when present in the corresponding patient tumors and do not appear de novo in mouse-
passaged xenografts from either primary (84) or metastatic samples (85, 99), including matched samples 
of primary tumors and synchronous or metachronous metastases (83, 141). An overall preservation of 
CNA and mutational landscape, with the caveat that the number of samples analyzed so far is limited, 
has also been observed in CRC organoids as compared with the corresponding patient tumors 
(84,121,142). However, CIN CRC organoids tend to tolerate mitotic errors, which results in the accrual 
of chromosome mis-segregations over time (143). Similarly, an accumulation of synonymous and 
nonsynonymous mutations has been noted during prolonged culturing of MSI CRC organoids (122). 
 
The hurdles of co-clinical trials 
A number of exploratory studies have shown the potential of PDXs for mirroring therapeutic response 
in the patients who contributed tumor samples; for instance, the clinical outcome of individuals who had 
received various chemotherapeutic regimens for the treatment of liver or peritoneal metastases reflected 
the objective response (or lack of it) monitored months or years before in patient-matched PDXs that 
had been established at the time of primary tumor resection (144). Similarly, when PDX models were 
generated from pretreatment core biopsies of BRAF mutant metastases and tested for their sensitivity to 
combined BRAF and MEK blockade, the objective response in mice was similar to the radiological 
response in the biopsied lesions (145).  
 
If patient-derived models are high-fidelity “avatars” of pre-derivation tumor samples, they could be used 
– in principle – for real-time assessment of drug sensitivity, which may be reverse-exploited to guide 
treatment decisions in donor patients. Co-clinical trials have been proposed in which PDX mice are 
treated with panels of drugs – either agents with broad-brush anticancer activity or targeted compounds 
based on molecular predictors; then, when a positive signal for a specific therapy emerges, the 
information is transferred back to the donor patient for clinical evaluation (81,146). While intriguing, 
an approach of this kind requires that therapeutic findings be univocally deciphered and rigorously 
interpreted. For example, spurious positive signals may arise for treatments that delay tumor growth, 
resulting in tumors that are smaller than untreated controls at end point, but larger than they were at 
treatment initiation. This outcome may be indicative of biological sensitivity (i.e., the drug reduces 
cancer cell proliferation) but has little clinical relevance; indeed, in patients, a lesion that enlarges during 
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treatment (even to a relatively small extent) denotes tumor progression, and the therapy is usually 
discontinued due to lack of efficacy.  
 
Another issue with the execution of PDX-based co-clinical trials is the need to cope with quick 
turnarounds. Results in mice must be promptly returned to donor patients to inform treatment decisions, 
but research with PDXs notoriously implies long-term and time-consuming experiments. “Cutting 
corners” in the name of rapidity, for example by reducing the number of animals tested in each treatment 
cohort, would lead to insufficiently powered studies and scientifically unreliable conclusions. Compared 
with PDXs, organoids are expected to speed up the bench-to-bedside pipeline due to their higher 
manageability. However, we are still missing metrics that adequately capture how and to what extent 
organoids deliver a clear prediction of the outcome in patients. There is no consensus on the adoption 
of common readouts of drug sensitivity (reduction of cell proliferation versus induction of apoptosis) 
and shared methodologies for data acquisition (digital imaging versus cell counts). Moreover, a direct 
comparison of the concordance between patient-matched PDXs and organoids in categorizing response 
or resistance to therapy has not been attempted so far on a systematic scale.  
 
PDX studies could also provide potentially useful real-time information about drug toxicity, but 
gathering generalizable data on this aspect will likely prove daunting. A meta-analysis of adverse events 
in mice treated with various therapies has revealed large deviations among different studies, with a 
variable extent of animal weight loss or death toll that was apparently independent of mouse strain and 
dosage and rather attributable to facility- and operator-related factors (147). This inconsistency is 
compounded by idiosyncratic liabilities of defined mouse strains; for instance, SCID mice harbor a loss-
of-function mutation in the catalytic subunit of DNA-dependent protein kinase, an enzyme required for 
efficient DNA double-strand break repair (148). Consequently, mouse strains that carry this mutation 
show increased total-body sensitivity to chemical or physical agents that damage DNA, such as 
irradiation, chemotherapy, and inhibitors of the DNA repair machinery. As always when dealing with 
resource platforms, standardized guidelines built on cumulative experience will be a prerequisite for 
direct transfer of preclinical results to patients. 
 
Integration of the tumor immune microenvironment: humanized mice and co-cultures 
The necessity of using immunocompromised mice to prevent xenograft rejection hampers the use of 
conventional PDX models to assess the efficacy of immunotherapies. Humanized mice are 
immunodeficient animals in which the human immune system is partially reconstituted by introducing 
CD34+ hematopoietic stem cells (HSCs), peripheral blood mononuclear cells (PBMCs), or tumor-
infiltrating lymphocytes (TILs) (6,149) (Figure 4). Attempts to generate humanized CRC models have 
been scant. Cell-line xenografts in mice engrafted with allogeneic or autologous human PBMCs showed 
delayed growth kinetics and increased infiltration of cytotoxic T cells after treatment with a combination 
of nivolumab and urelumab, a CD137 agonist monoclonal antibody that enhances T‐cell and natural 
killer‐cell antitumor activity (150). Similar results were observed in a dMMR/MSI-H PDX model, but 
not in a microsatellite stable model, after humanization with cord blood-derived CD34+ cells and 
treatment with nivolumab (151).  
 
Although humanized mice appear to recapitulate some of the effects of immunotherapy observed in 
patients, the procedure of mouse humanization is afflicted with several drawbacks. PBMC and TIL 
infusion typically causes severe graft-versus-host disease starting 2-5 weeks after injection (152,153), 
which restricts the investigative window to temporal limits that are hardy compatible with experimental 
needs. Transplantation of HSCs results in a more complete hematopoietic reconstitution, but their 
maturation as well as the effector functions of their differentiated progeny are compromised by the lack 
of cytokines, phagocytes, and HLA molecules of human origin in the mouse host. The application of 
genome editing technologies for mouse genetic engineering is expected to increase the extent of 
humanized cells and molecules in future murine models. 
 
Another emerging asset to reconstruct the functional interactions between cancer cells and the immune 
microenvironment relies on hybrid organ-on-a-chip platforms, which allow the build-up of more 
complex multicellular systems (154). Reductionist methodologies involve the initial establishment of 
separate cultures of epithelial organoids and immune cells, followed by artificial reconstitution in co-
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mingling experiments. This approach has been used to set up co-cultures of cancer cells from primary 
or metastatic CRC with high mutational burden and autologous PBMCs, wherein cancer cell organoids 
triggered antigen-specific stimulation of tumor-reactive cytotoxic T cells in the PBMC fraction (155) 
(Figure 4). More sophisticated air-liquid interface (ALI) methods have also been deployed that enable 
the en bloc preservation of the tumor epithelium and its endogenous immune stroma, including 
fibroblasts, tumor-associated macrophages, T and B lymphocytes, and natural killer cells (156). ALI 
cohesive units propagated from CRC biopsies retained the T cell receptor heterogeneity of the T cells 
present in original tumors and modeled the effects of nivolumab by recapitulating cytotoxic T cell 
expansion and antibody-dependent tumor cytotoxicity (156) (Figure 4). Further complexity could be 
achieved by integrating on-chip tumor immune microenvironments with biomimetic vascular-like 
structures for reconstitution of physiological functions of the microvascular tissue. This methodology 
has been used to develop a 3D chip-based model comprising a human CRC core and a surrounding 
vascularized network (157) and, in principle, might be upscaled to include microfluidic co-cultures of 
immune cells. Assessing the functional consequences of immune checkpoint blockade using advanced 
organoid technology is poised to complement existing descriptive biomarkers, such as neoantigen load, 





The clinical and experimental observations discussed above illustrate the power of population-level 
studies – both in patients and in the preclinical setting – to credential candidate predictive biomarkers 
and identify novel determinants of therapeutic response as well as novel targets. Recent evidence also 
highlights the value of patient-derived xenografts and organoids as tools to investigate subclonal 
dynamics during tumor evolution and functional heterogeneity under drug pressure. The credibility of 
patient-derived models in preserving the molecular architecture of the corresponding pre-derivation 
tumors is now supported by large-scale analytical efforts and the use of accurate genomic approaches. 
These merits notwithstanding, several issues remain, which are mostly related to the inability of PDXs 
and organoids to recapitulate heterotypic interactions between cancer cells, stromal cells, and immune 
cells. Mouse humanization procedures and co-culture assays are expected to aid the development of 
more holistic models that incorporate immune components. However, the impact of bone marrow 
reconstitution (let alone that of PBMC or TIL infusion) on the quality, quantity and topographical 
localization of immune infiltrates in transplanted tumors is difficult to assess, as is the influence of the 
host on the differentiation trajectories and functionality of transplanted human HSCs. Likewise, 
cocultures of cancer cell organoids with endogenous, syngeneic immune cells fail to mimic the subtleties 
of the tumor microenvironment in terms of complexity, representation, and reciprocal distribution of 
immune components. Another dimension of complexity is the difficulty – if not the impossibility – of 
replacing stromal elements such as endothelial cells and fibroblasts with their human counterparts; 
hence, the limitation remains that mouse-derived cytokines and growth factors in some cases do not 
crossreact with receptors that are expressed by human cancer cells. 
 
A careful appraisal of the (vast) extent of information that can be reliably garnered by the use of patient-
derived models, but also a clear understanding of their shortcomings, will be key to deliver robust, 
predictive and translationally relevant knowledge. This critical attitude will help triage and move to the 
clinic only those findings that emerge from conclusive and generalizable preclinical research and are 
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LEGENDS TO FIGURES 
 
Figure 1: Application of colorectal cancer PDXs in translational research. PDX trials are conducted 
in parallel with or after clinical trials to “reverse validate” response biomarkers and genotype-response 
associations identified in patients (left panel). Cells dissociated from PDXs can be genetically 
manipulated and used in lineage tracing experiments to assess the temporal and spatial dynamics of 
functionally heterogeneous clones under drug pressure (middle panel). Genomic analysis of large-scale 
PDX collections enables the discovery of molecularly defined CRC subpopulations, which can be tested 
for the presence of potential therapeutic targets through pharmacologic experiments in vivo (right panel). 
 
Figure 2: Application of genetically modified animal models of colorectal cancer in translational 
research. Genetically modified mice carrying targeted gene recombination of common mutations (Apc, 
Kras, Tgfbr2 and Trp53) in intestinal stem cells develop immune-cold CRC tumors with high levels of 
stromal TGF-; blockade of TGF- signals prompts the recruitment of immune effector cells into the 
tumor microenvironment and sensitizes tumors to immunotherapy (left panel). Another mouse model 
develops metastatic CRC featuring a pronounced stromal reaction due to targeted expression of active 
Kras and Notch and loss of Trp53 in villin-positive intestinal cells; Notch-dependent production of TGF-
 by cancer cells promotes tumor infiltration by neutrophils and metastatic dissemination, which can be 
blunted by inhibition of neutrophil recruitment or TGF- signaling (right panel). 
 
Figure 3: Application of CRC organoids in translation research. Patient-derived organoids from 
normal colon can be engineered to express drivers of colorectal tumorigenesis, alone and in 
combination; this approach allows to explore the contribution of each driver to tumor onset and 
progression and helps understand how and to what extent engineered organoid models recapitulate the 
biological characteristics of spontaneous tumors from patients (left panel). Mutational profiles, 
methylomics and/or RNA sequencing analysis of clonal organoids derived from individual cells of 
patients’ tumors can be used to reconstruct phylogenetic trees and investigate CRC tumor evolution 
(middle panel). Organoids can be exploited in mid- to high-throughput drug screens, and results from 
pharmacologic analyses can be coupled with molecular profiles to extract associations between drug 
sensitivity and specific molecular traits (right panels). 
 
Figure 4: Incorporating the immune system into patient-derived models. The immune system of 
immunocompromised mice can be partially reconstituted with different approaches of variable efficacy, 
from infusions of PBMCs or TILs to transplantation of HSCs derived from the bone marrow or umbilical 
cord blood; once humanized, mice can be xenografted with patient-derived tumors and treated with 
immunotherapy to assess tumor growth kinetics and intratumor representation of immune cells before 
and after treatment (left panel). Cocultures of immune cells and cancer cells can be performed by co-
mingling tumor organoids and autologous PBMCs or by implementing ALI methods that allow the 
preservation of the tumor epithelium and the associated immune stroma in cohesive units; both 
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Stratification of colorectal cancer (CRC) into subgroups that differ in their response to therapy was 
initially informed by correlative studies in patients, which were based on statistical associations 
between the presence of specific biomarkers and treatment outcome. Recently, preclinical model 
systems based on propagatable patient-derived tumor samples (xenografts and organoids) have yielded 
an improved understanding of disease biology, which has translated into the functional validation of 
descriptive correlations and the discovery of novel response determinants, therapeutic targets, and 
mechanisms of tumor adaptation and drug resistance. We critically review the contribution of patient-
derived tumor models to advancing CRC molecular characterization, discuss their influence on clinical 
decision-making, and highlight emerging challenges in the interpretation and clinical transferability of 





Association studies in patients with CRC have led to the identification of response biomarkers, some 
of which have been implemented as companion diagnostics for therapeutic decisions. By enabling 
biological investigation in a clinically relevant experimental context, patient-derived CRC models 
have proved useful to model the causal role of such biomarkers in dictating drug sensitivity and are 
providing fresh knowledge on new actionable targets, dynamics of tumor evolution and adaptation, 








Colorectal cancer (CRC) is the third most frequent cause of cancer-related deaths in both the United 
States and Europe [1, 2]. Around 25% of individuals harbor metastatic disease at the time of diagnosis, 
while approximately 50% of patients will develop metastases later [3] . Although 5-year survival rates 
experienced by patients with metastatic CRC (mCRC) remain low (14%) [1], therapeutic options 
developed in the past two decades have prolonged the median overall survival (OS) from 12 to 30 
months [4]. This survival advantage can be attributed to improved surgical techniques and the use of 
more effective systemic therapies. At least partially, more informed treatment decisions based on 
molecular response predictors have also helped increase life expectancy, but biomarker recognition 
has been slow and often inconclusive due to the difficulty of substantiating correlative observations in 
patients with functional investigation in clinically relevant model systems. Similarly, while genomic 
datasets have offered an instructive compendium of the genes that are frequently altered in CRC [5], 
the question whether the aberrant protein products of such genes represent effective therapeutic targets 
remains hard to address in the absence of adequate translational tools. 
 
The availability of large collections of patient-derived tumor samples that can be propagated in mice 
(xenografts) and in three-dimensional cultures (organoids) has spearheaded attempts to afford 
biomarker-response associations with mechanistic annotation and has facilitated studies aimed to 
model cancer progression and acquisition of drug resistance [6, 7]. Herein, we provide an overview of 
current therapies and related biomarkers, as implemented in patients with mCRC, and discuss how 
patient-derived xenografts and organoids have been deployed to go beyond correlative descriptions 
and to illuminate fundamental biological and clinical aspects of CRC, including drug repurposing 
efforts that have rapidly moved to the clinical space. Further, we consider the practical implications 
and the limitations of using such models in terms of clinical applicability and predictivity.  
 
 
Empirical and biomarker-driven treatments: Correlative response predictors in patients 
 
The standard-of-care treatment for mCRC patients includes cytotoxic agents and biological targeted 
compounds, which are administered cumulatively based on the empirical observation that multi-agent 
therapeutic cocktails are more effective than monotherapies [8, 9]. Although some patients receive 
important clinical benefit from these regimens, responses are typically limited to a fraction of 
individuals. The polarized distribution of responsive and non-responsive patients likely derives from 
the genomic and functional heterogeneity of mCRC tumors, which display patient-to-patient molecular 
differences that influence treatment outcome. While the application of ‘omics’ technologies has been 
instrumental to enrich for potential responders to targeted therapies, this has been unsuccessful for 
chemotherapy, in part due to its often incompletely understood and diverse mechanisms of action.  
 
Chemotherapy 
The fluoropyrimidine antimetabolite 5-fluorouracil (5-FU) is injected intravenously together with 
leucovorin (LV), a biomodulator of 5‐FU that has been shown to enhance its activity. Capecitabine, 
another fluoropyrimidine, is given orally. 5-FU/LV is most often administered in combination with 
oxaliplatin, a platinum compound endowed with inter- and intra-strand DNA cross-linking activity 
(FOLFOX) [10], or irinotecan, a topoisomerase I inhibitor (FOLFIRI) [11]. Either combination is 
more effective than 5-FU/LV alone in increasing response rates and prolonging progression-free 
survival (PFS), but at the cost of more pronounced toxicity [10-12]. The triplet association of 5-
FU/LV, oxaliplatin and irinotecan (FOLFOXIRI) is also being increasingly used in mCRC patients 
with adequate performance status [13-15]. Other therapeutic options include capecitabine plus 
oxaliplatin (CAPOX/XELOX) and capecitabine plus irinotecan (XELIRI). CAPOX/XELOX has 
shown analogous efficacy and safety compared to FOLFOX and it is now proposed as first- or second-
line therapy in patients refractory to irinotecan-based chemotherapy [16]. In the case of XELIRI, the 
phase 3 trials BICC-C and EORTC-415 have documented severe gastrointestinal side-effects 
compared to FOLFIRI [17, 18]. However, a modified regimen with reduced doses of both capecitabine 
and irinotecan (mXELIRI) was well tolerated, proved to be non-inferior to FOLFIRI in terms of OS, 
and is now proposed as an alternative second-line backbone treatment [19]. In patients who have 
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progressed after all standard therapies, a statistically significant (but modest) improvement in OS can 
be obtained with TAS-102, an agent that combines trifluridine (a nucleoside analog) and tipiracil 
hydrochloride (an inhibitor of thymidine phosphorylase) [20].  
 
Potential determinants of response to chemotherapy have been brought to the fore based on the 
mechanism of action and metabolism of the various agents. However, the application of such 
predictors in clinical practice has been hampered by inconsistent results among different case series 
and poor diagnostic sensitivity and specificity. In some instances, in consonance with data from 
targeted therapies, drug target overexpression may be a positive determinant of sensitivity. For 
example, high expression of thymidylate synthase (TS), a direct target of 5-FU, has been associated 
with longer survival in CRC patients treated with adjuvant 5-FU-based therapy in some studies [21, 
22]; however, other reports have not confirmed the positive predictive value of TS overexpression [23, 
24] (Table 1). Likewise, elevated levels of topoisomerase 1 appear to predict better response to 
irinotecan [25] (Table 1). The activity of drug metabolic pathways is also likely to affect 
chemosensitivity. Dihydropyrimidine dehydrogenase (DPD) is a rate-limiting enzyme in 
fluoropyrimidine catabolism. High expression of DPD has been documented in tumors from patients 
with reduced sensitivity to capecitabine [26], with or without irinotecan [27], whereas inactivating 
polymorphisms of the DYPD gene (encoding DPD) have been associated with acute toxicity over the 
course of fluoropyrimidines-based therapy [28-30] (Table 1). In the same vein, deleterious 
polymorphisms of the UGT1A1 gene (encoding glucuronosyltransferase, a key enzyme of irinotecan 
metabolism) are more frequent in patients who experience severe toxicity during treatment with 
irinotecan-based regimens [31, 32] (Table 1). 
 
Responsiveness to chemotherapy may also be related to defects in DNA repair mechanisms after 
chemotherapy-induced DNA damage, leading to abnormalities in DNA replication and/or 
chromosome segregation that culminate in cancer cell death. Excision repair cross-complementation 
group 1 (ERCC1) is a key effector of DNA repair mechanisms and influences the tumor DNA-
targeting effect of oxaliplatin. Some studies have shown that low transcript expression of the ERCC1 
gene correlates with longer survival of patients treated with FOLFOX [33] (Table 1). Similar findings 
were reported for an ERCC1 polymorphism at codon 118, which is expected to result in decreased 
ERCC1 gene expression [34] (Table 1). These correlations, however, have not been confirmed in other 
datasets, especially when ERCC1 protein amounts rather than transcript expression were analyzed [35, 
36]. Functional studies are needed to deepen mechanistic investigation of the relationship between 
DNA repair deficiency and chemosensitization. More in general, we advocate a revamping of 
biologically oriented research as a means to disentangle the intricacies behind chemotherapy efficacy 
(or lack of), including the evaluation of how genetic and epigenetic modifications in components of 
DNA repair pathways shape response to cytotoxic agents. A clearer understanding of the cellular and 
molecular underpinnings of chemotherapy activity in clinically relevant experimental models is a 
necessary prelude to the nomination of response biomarkers above and beyond descriptive variables in 
patients. 
 
EGFR monoclonal antibodies 
The EGFR monoclonal antibodies cetuximab and panitumumab are currently used in association with 
FOLXOX or FOLFIRI in the first- or second-line treatment of patients with KRAS or NRAS wild-type 
tumors [37]. The restricted use of anti-EGFR antibodies to patients with RAS wild-type mCRC is the 
result of a population-level biomarker-development strategy motivated by the plausible rationale that 
constitutive activation of signaling pathways downstream from EGFR – such as those triggered by 
RAS mutations – should bypass EGFR inhibition and therefore obviate sensitivity to EGFR targeted 
agents. Evidence of the correlation between RAS genetic alterations and lack of response to EGFR 
blockade was initially limited to tumors with exon 2 KRAS mutations [38] and was later extended to 
KRAS exons 3 and 4 and NRAS exons 2, 3 and 4 [39] (Table 1). The predictive value of the association 
was so strong that retrospective studies in patients were deemed sufficiently powered to guide the 
development of companion diagnostics for the routine assessment of “RAS extended” mutations in 




While the use of RAS mutation panels for the exclusion of mCRC patients who will not benefit from 
anti-EGFR therapy is now commonplace, the quest for positive response predictors has lagged behind. 
EGFR is hardly ever mutated or amplified in CRC, indicating that tumor dependency on the EGFR 
pathway does not have an evident genetic basis. Retrospective correlative studies have documented 
higher tumor expression of the EGFR ligands amphiregulin and epiregulin in patients who respond to 
EGFR antibodies [40, 41] (Table 1). Hence, mCRC tumors that are sensitive to EGFR neutralization 
appear to rely on EGFR signals owing to ligand-mediated autocrine or paracrine receptor activation. 
This knowledge has not translated into clinical-grade methods for selection of potential responders due 
to the difficulty of dichotomizing continuous variables, such as transcript or protein expression, into a 
digital cut off for univocal allocation of patients to treatment. 
 
Anti-angiogenic therapy 
The first-line treatment for patients with mCRCs harboring KRAS or NRAS mutations comprises either 
FOLFIRI or FOLFOX plus the anti-VEGF antibody bevacizumab [42, 43]. Whether the addition of 
VEGF-targeting agents to chemotherapy provides comparable or superior benefit to anti-EGFR 
antibodies in the context of KRAS/NRAS wild-type tumors is still a matter of debate [44]. Beyond 
bevacizumab, two other anti-angiogenic drugs have been proved to positively impact on PFS and 
response rates when combined with chemotherapeutic agents in late lines of treatment: aflibercept (an 
anti-VEGF-A, VEGF-B, and placental growth factor) [45] and ramucirumab (an anti-VEGF receptor 
2) [46]. Finally, heavily treated chemorefractory patients can experience slightly longer OS when 
treated with the multikinase inhibitor regorafenib, which also targets pro-angiogenic receptors [47]. 
 
At present, there are no validated predictors of response to anti-angiogenic agents [48]. Clinical 
reports have shown a correlation between more marked responsiveness to bevacizumab and low 
baseline levels of VEGF-A splice isoforms [49], VEGF-D [50], HGF [51], interleukin-8 [52] or the 
VEGF-A coreceptor neuropilin-1 [53], either in plasma or tumors (Table 1). Germline polymorphisms 
of VEGF-A [54, 55], VEGF receptor-1 [56] and inflammation- and endoplasmic reticulum-associated 
genes [57] also show a significant interaction with bevacizumab effectiveness (Table 1). Other 
potential biomarkers predicting bevacizumab therapeutic efficacy include loss of chromosome 
18q11.2-q12.1 [58] and, more in general, a high degree of chromosomal instability (CIN) [59] (Table 
1). In the case of regorafenib, initial studies suggest that low expression of vascular cell adhesion 
protein 1 (VCAM-1) may be associated with better response [60] (Table 1). Polymorphisms of genes 
related to the C-C motif chemokine ligand 5/C-C motif chemokine receptor 5 pathway (which 
regulates VEGF-A expression) also predict efficacy in mCRC patients treated with regorafenib [61] 
(Table 1).  
 
The fact that the expression levels of angiogenic targets positively associate with sensitivity to anti-
angiogenic agents has a pharmacokinetic basis ascribable to the relative stoichiometry of drug-target 
interactions. The biological significance of other candidate biomarkers, such as copy number 
alterations, is of difficult interpretation in the absence of functional modeling in adequate experimental 
systems. Mechanistic investigation of stromal-directed therapies is complicated by a dearth of 
preclinical resources, which typically consist of syngeneic transplants, genetically modified mice, or 
xenografts. All approaches have limitations: on the one hand, “mouse-only” models hardly 
recapitulate the inter-patient heterogeneity and population diversity of human tumors – a severe 
drawback for biomarker discovery research; on the other hand, xenografts are by definition a chimeric 
source of angiogenic factors, which can be concomitantly released by human cells of the tumor and 
murine stromal and inflammatory cells of the host. Therefore, due to species specificity, the cross-talk 
between heterologous cellular compartments is biased, and therapeutic antibodies cannot have full 
capacity at the organismal level because they selectively target either murine or human antigens.  
 
Other targeted therapies 
All the above therapies are administered in the absence of positive molecular selection; the only 
criterion is patient exclusion based on the presence of negative response biomarkers, as epitomized by 
the established association between KRAS/NRAS mutations and lack of response to EGFR blockade. 
Recently, a number of low-frequency aberrations in kinase-encoding genes have been identified in 
mCRC that result in constitutive activation of the corresponding protein products. Alterations in the 
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ERRB2 gene (mostly gene amplification) are detected in around 5% of KRAS, NRAS or BRAF wild-
type mCRCs and lead to overexpression and hyperactivation of the encoded HER2 tyrosine kinase 
receptor. Phase 2 studies in patients selected for having HER2-positive mCRC tumors have shown that 
dual inhibition of HER2 using the anti-HER2 antibody trastuzumab and the EGFR/HER2 small-
molecule inhibitor lapatinib (HERACLES trial) or the combination of trastuzumab and the anti-HER2 
antibody pertuzumab (MyPathway trial) have considerable clinical efficacy, with around 30% 
response rates in heavily pretreated patients [62, 63] (Table 1). Notably, in both studies responsive 
patients had tumors with higher ERBB2 gene copy number than resistant patients, consistent with the 
assumption that higher ERBB2 gene dosage translates into stronger kinase activation, hence in more 
profound tumor dependency on HER2 signaling.  
 
Kinase fusions originating from chromosomal translocations and resulting in constitutive activation of 
neurotrophic receptor tyrosine kinase 1 (NTRK1), NTRK2, NTRK3, anaplastic lymphoma kinase 
(ALK), and RET account for approximately 1-2% of KRAS, NRAS or BRAF wild-type mCRCs. These 
rearrangements are enriched in right-sided RAS wild-type tumors and, while typically portending a 
dismal prognosis [64], they predict therapeutic benefit of inhibitors such as entrectinib (targeting 
NTRK, ROS1 and ALK) [65, 66] and ponatinib (targeting various tyrosine kinases including RET) 
[67, 68] (Table 1). 
 
BRAF gene alterations (with a dominant prevalence of V600E activating mutations) are found in 7-
10% of mCRCs [69, 70] and are generally mutually exclusive with KRAS and NRAS mutations, 
indicating that a single oncogenic hit on the ERK MAPK pathway is sufficient to sustain 
tumorigenicity. The most recent guidelines recommend an upfront intensified regimen with triplet 
chemotherapy (FOLFOXIRI) plus bevacizumab, a schedule that – however – is not limited to BRAF 
mutant tumors. Selective BRAF targeting with specific inhibitors has proven ineffective in patients 
with BRAF-mutant mCRC due to feedback reactivation of EGFR signaling, which substitutes for 
BRAF blockade in stimulating the MAPK pathway [71, 72]. This observation has prompted the design 
of clinical trials aimed at evaluating the efficacy of combined BRAF and EGFR inhibition in patients 
with BRAF mutant mCRC. In a recent phase 3 study testing cetuximab and the BRAF inhibitor 
encorafenib versus cetuximab and irinotecan (or FOLFIRI), combined EGFR and BRAF blockade 
significantly improved response rates and OS compared with standard therapy. This superior activity 
was further enhanced by concomitant MEK inhibition [73] (Table 1). These results have led to the 
FDA approval of encorafenib plus cetuximab in previously treated patients with BRAF mutant mCRC. 
 
Despite their high prevalence (approximately 50% of all CRCs), KRAS and NRAS mutant tumors are 
still treated with conventional chemotherapy and anti-angiogenic agents. Hopes are now placed on the 
use of KRAS G12C covalent inhibitors, which are currently tested in patients with KRAS G12C solid 
tumors. Initial results seem to indicate that response rates to these drugs are relatively high in patients 
with non-small cell lung cancer but limited in mCRC patients, likely due to retained sensitivity of 
CRC tumors to upstream EGFR signaling [74] (Table 1). These observations echo findings in BRAF 
mutant tumors [71, 72] and strengthen the notion that EGFR signaling needs to be concomitantly 
neutralized to achieve better responses to drugs targeting the RAS-MAPK pathway in mCRC. 
 
Immunotherapy 
About 15% of CRCs display defective functionality of mismatch repair (MMR) proteins, which 
participate in the correction of base-pair mismatches occurring during DNA replication (especially at 
the level of repetitive DNA sequences called microsatellites). Deficient-MRR (dMMR) tumors with 
mutations in 30% or more microsatellites (defined as dMMR/MSI-H, i.e. with high microsatellite 
instability) tend to accumulate nonsynonymous mutations; this increased mutational burden can 
translate into a higher neoantigen load, which makes some dMMR/MSI-H tumors immunogenic and 
sensitive to immune checkpoint blockade [75]. Accordingly, single-agent therapy with the anti-PD-1 
antibodies pembrolizumab or nivolumab and combination therapy with nivolumab and the anti-CTLA-
4 antibody ipilimumab have been approved for second-line treatment of patients with chemorefractory 
dMMR/MSI-H mCRC [76-78] (Table 1). Based on recent data from the phase 3 KEYNOTE-177 trial, 
pembrolizumab appears to be superior to standard-of-care chemotherapy in improving PFS in the first-
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line setting; this information has led to the FDA approval of pembrolizumab as first-line therapy for 
patients with unresectable or metastatic dMMR/MSI-H colorectal cancer [79]. 
 
The assessment of MSI status is now routinely performed for selecting patients likely to respond to 
immunotherapy, but only a subgroup of individuals with MSI mCRC receive clinical benefit from this 
treatment. Not always are the protein products of somatic DNA variants efficiently presented by MHC 
molecules, which means that tumor mutational burden only partially contributes to neoantigen load. 
Likewise, although an association between high neoantigen load and pronounced immune cell 
infiltration has been repeatedly documented, the presence of an active immune microenvironment has 
not predictive value for immunotherapy sensitivity [80]. HLA binding prediction tools and artificial 
intelligence algorithms for multiparametric imaging of immune cell representation and topography in 
tumors are expected to yield more reliable molecular biomarkers for effective patient stratification in 
the immuno-oncology space. 
 
 
Preclinical models for understanding and predicting therapeutic response in CRC 
 
Biomarkers that predict patient response to treatment are usually identified using population-based 
association studies, in which clinical outcome is correlated with a statistically significant enrichment 
for a specific molecular trait (typically, a genetic alteration) in subjects who do or do not respond to a 
given therapy. Albeit useful for clinical decision making, this approach fails to inform whether 
therapeutically relevant response predictors causally influence drug sensitivity and does not provide 
insight into the mechanistic underpinnings of the observed correlations. In a complementary 
perspective, studies using cancer cell lines enable extracting functional annotations and modeling 
cause-effect relationships; however, cell lines are by definition limited in number; thus, they do not 
recapitulate the spectrum of genetic heterogeneity spanned by patient tumors. Recently, patient-
derived platforms that reflect the diversity of cancers, while retaining experimental manipulability and 
clinical fidelity, have been developed with the aim to characterize response biomarkers, investigate 
tumor adaptation under drug pressure, and understand the evolutionary principles of tumor 
progression. CRC has been – and still is - a testing arena for such efforts. 
 
Patient-derived xenografts (PDXs) for validation of targeted therapy biomarkers 
Surgically derived tumor samples that are implanted in mice (known as patient-derived xenografts, 
PDXs) retain the inherent features of different tumors from different patients [6, 81]. Vast PDX 
collections are therefore expected to capture inter-patient tumor heterogeneity at the population level 
in a clinically relevant in vivo setting [82]. CRC is a paradigmatic example of the importance of PDX-
based research for large-scale genotype-response associations, predictive biomarker identification, and 
therapeutic studies [83, 84] (Figure 1). In 2011 a systematic survey of KRAS and NRAS mutations in 
more than 100 mCRC PDXs, coupled with annotation of sensitivity to cetuximab, produced a dataset 
with both confirmatory and discovery aspects [85]. On the one hand, the association between KRAS 
mutations in exon 2 and de novo resistance to EGFR blockade – which had emerged from clinical 
studies some years earlier [86] – was ‘reverse validated’ in PDXs and found to be coherent with 
patient data [85] (Table 1). On the other hand, results in PDXs were among the first to illustrate that 
KRAS mutations in exons 3 and 4 and NRAS mutations predict lack of response to EGFR antibodies 
[85, 87]. This finding would receive ultimate clinical recognition only two years later, when a 
retrospective-prospective analysis concluded that patients with tumors harboring ‘RAS extended’ 
mutations treated with anti-EGFR antibodies had inferior PFS and OS compared with patients with 
KRAS/NRAS wild-type tumors [39].  
 
While PDXs appear to have adequate predictive power for cancer cell-directed treatments, they lose 
value when dealing with therapies against stromal components – such as cancer-associated fibroblasts, 
endothelial cells, and inflammatory cells – and cells of the adaptive immune system. Indeed, the host 
must be immunocompromised to tolerate the graft, and human stromal cells are substituted with 
murine counterparts over serial passaging [6]. But this drawback bears some advantages: the chimeric 
nature of PDXs has been leveraged to decompose – from bulk tumors – cancer cell-specific and 
stromal signals using analytical methods that distinguish human versus mouse transcripts. This 
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exercise has increased the granularity and informative merit of gene expression classifications. For 
example, the clinical aggressiveness of a poor-prognosis transcriptional subtype named CMS4 had 
been initially ascribed to the ability of cancer cells to undergo epithelial-mesenchymal transition 
(EMT), a phenotypic switch that instigates cell motility and invasion [8, 88]. With the possibility to 
discriminate between human and mouse transcripts, it became clear that – together with displaying 
some cancer cell-autonomous EMT traits – the vast majority of mesenchymal CMS4 tumors are in fact 
characterized by a heavy content of stromal cells, which likely foster the malignant characteristics of 
this subtype by conveying mitogenic, pro-invasive and anti-apoptotic cues [89]. In the same vein, 
CRIS, a new CRC classification based only on PDX human transcripts, identified subtypes endowed 
with prognostic and predictive significance and showing limited overlap with transcriptional classes 
obtained from whole bulk CRCs [90]. Moreover, by focusing on cancer-cell intrinsic gene expression 
features that are not influenced by stromal abundance in isolated, randomly taken tumor samples, 
CRIS demonstrated higher accuracy in clustering CRCs by patient-of-origin rather than tumor region-
of-origin [91]. 
 
PDXs to study the clonal dynamics of CRC tumors under chemotherapy pressure 
Tumors are composed of heterogeneous cell subsets that display different proliferation kinetics, 
susceptibility to apoptosis, and sensitivity to drug insults [92]. Some works have used PDX models to 
investigate the clonal propagation dynamics of CRC subpopulations, both during spontaneous tumor 
growth and under drug pressure (Figure 1). DNA copy number alteration profiling and deep 
sequencing of mutational hotspots were combined with lentiviral lineage tracking to follow the 
progeny of single CRC cells over serial xenografts and to investigate the relative contribution of 
genetic and nongenetic mechanisms to the functional heterogeneity of the individual cancer cells [93]. 
While genetically identical clones remained stable upon serial transplantation, lentivirally marked 
lineages were variable within each clone, with pronounced differences in proliferation rates, ability to 
persist, and susceptibility to exhaust through passages [93]. Likewise, treatment of xenografts with 
irinotecan did not result in a detectable bottleneck or selection for novel genetic clones; rather, 
chemotherapy shaped a new dominance of previously dormant lineages and culled actively 
proliferating progeny [93]. Together, these results indicate that cancer cells subpopulations can be 
genetically homogeneous (and stable) but functionally heterogeneous (and plastic) in CRC. 
 
The finding that CRC cancer cells oscillate between periods of dormancy and activity appears to have 
a positional determination. Using a tamoxifen-inducible labeling system to stochastically mark cancer 
cells in mouse xenografts of patient-derived spheroids, coupled with computational modeling, Lenos 
and colleagues documented that CRC grows through surface expansion [94]. This peripheral accretion 
is driven by the local availability of mitogenic gradients secreted by cancer-associated fibroblasts, 
which are sensed only by cancer cells located in the outermost zone of the tumor [94] (Figure 1). 
Chemotherapy with 5-FU and oxaliplatin reduced tumor growth rates but did not affect the residual 
dynamics of surface growth, indicating that microenvironmental influences dictating spatially 
confined cell proliferation are not interfered by cytotoxic treatment [94]. Other studies with multicolor 
lineage tracing approaches in xenografts of CRC primary cultures and cell lines confirmed that tumor 
outgrowth is geometrically orchestrated by large proliferating clones confined at the leading tumor 
edge, whilst small quiescent clones reside in the center [95, 96]. 
 
PDXs and genetically modified animal models for target discovery  
Besides providing preclinical hints for response biomarker validation, PDXs have also been deployed 
for testing therapeutic options in newly identified, molecularly circumscribed mCRC subsets (Figure 
1). Amplification of the ERBB2 oncogene was detected in some KRAS/NRAS wild-type, cetuximab-
resistant PDX models, and was found to predict response to HER2 targeted therapies in PDX-based 
preclinical trials [85, 97] (Table 1). Other clinically actionable alterations were shown to be enriched 
in KRAS/NRAS wild-type, cetuximab-refractory PDXs and patients, including activating mutations of 
ERBB2 and MAP2K1 (encoding the RAS downstream effector MEK1), amplification of the tyrosine 
kinase receptors MET and FGFR1, and outlier overexpression of the survival factor IGF2 [98-101]. In 
general, the sole inhibition of the hyperactive oncoproteins proved to be ineffective in PDXs, but 
treated tumors were invariably sensitized to concomitant EGFR blockade. Subsequent clinical studies 
confirmed that patients with HER2-positive mCRC tend to respond poorly to EGFR antibodies and 
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can benefit from dual treatments against HER2 and EGFR [62, 63]. Similarly, MEK1 mutations were 
found to predict resistance to EGFR inhibition and response to a combination of trametinib (a MEK 
inhibitor) and panitumumab in patients [102]. 
 
PDXs have been shown to recapitulate clinical reality also in terms of depth of response. Similar to 
metastases in patients, mCRC PDXs that respond to EGFR antibodies can experience massive 
shrinkage but are hardly ever eradicated. The residual cancer cells that withstand upfront drug 
treatments act as a reservoir for the stochastic acquisition of resistance-conferring mutations, with the 
ensuing expansion of subclones responsible for tumor relapse [103]. Recent evidence indicates that 
residual mCRC PDXs (and residual tumors in patients) at maximal response to prolonged anti-EGFR 
therapy relax their dependency on EGFR signals by reducing the expression of genes encoding EGFR-
activating ligands and increasing alternate HER2/HER3 pathway activity, while becoming similar to 
slowly-cycling secretory precursors of the normal intestine [104]. The finding that cetuximab-tolerant 
residual tumors exhibit decreased abundance of EGFR cognate ligands is consistent with the clinical 
observation that patients with mCRC tumors expressing low levels of amphiregulin and epiregulin 
tend to respond less to EGFR antibodies [40, 41] (Table 1). Pseudodifferentiation into tissue-specific 
lineages has been documented as a mechanism of therapy resistance in other tumors; for example, the 
manifestation of neuroendocrine traits is a hallmark of emerging resistance to EGFR inhibitors and 
anti-androgen treatment in lung and prostate cancer, respectively [105, 106]. In the context of CRC, 
cetuximab-induced phenotypic reprogramming towards a secretory fate with high HER2/HER3 
signaling makes cancer cells vulnerable to concomitant targeting of EGFR, HER2 and HER3, as 
shown by reduction of residual disease burden and prolonged time to relapse after treatment 
discontinuation in PDX trials with a Pan-HER antibody [104]. 
 
As noted above, PDXs are inadequate tools for predicting response to therapies against stromal and 
immune cells. Genetically modified mouse models develop autochthonous CRC tumors in an immune-
competent background, but the artificial introduction of founder oncogenic mutations may result in 
evolutionary trajectories different from those occurring in spontaneous tumors [107]. This limitation 
has been addressed by engineering the ordered expression of salient mutant oncoproteins along the 
linear progression sequence that typifies human CRC, with the aim to more faithfully recapitulate the 
natural history of human tumors (Figure 2). Animals with targeted gene recombination of common 
mutations (Apc, Kras, Tgfbr2, and Trp53, known as AKTP) to intestinal stem cells developed invasive 
CRC adenocarcinomas with hallmarks of human microsatellite-stable tumors, including low 
mutational burden and scant T-cell infiltration [108]. Moreover, AKTP tumors had an abundant 
representation of carcinoma-associated fibroblasts engaged in massive deposition of extracellular 
matrix and profuse secretion of TGF-. Importantly, increased TGFβ in the tumor microenvironment 
was found to be a major determinant of T-cell exclusion, and blockade of TGFβ signaling rendered 
tumors more T cell-inflamed and susceptible to immunotherapy [108] (Figure 2). Another mouse 
model harboring Kras and Trp53 mutations along with hyperactive Notch signaling in intestinal cells 
developed metastatic tumors with serrated morphology, extensive stromal content, and gene 
expression profiles similar to those of poor-prognosis tumors in patients [109]. In these mouse tumors, 
hyperactivation of the Notch pathway resulted in secretion of TGF- by cancer cells, which prompted 
neutrophil accumulation in the tumor stroma and neutrophil-dependent metastatic dissemination. 
Accordingly, targeting neutrophil recruitment or TGF-β signaling reduced metastatic burden [109] 
(Figure 2). Collectively, these results underscore the value of transgenic mice as investigational 
models to explore the interplay between genetic alterations and the immune-competent tumor 
microenvironment and to integrate PDX-based research on cancer cell-intrinsic vulnerabilities. 
 
Patient-derived organoids for mechanistic investigation and pharmacologic studies  
PDXs represent more authentic working models than conventional cell-line xenografts to study how 
cancer cells evolve and react to therapies in a clinically relevant scenario that reflects organismal 
complexity. However, PDXs are not endowed with sufficient experimental tractability to distill 
causality from description, nor do they show sufficient scalability to enable high-throughput 
pharmacogenomic screens. Short-term culture of tumor sections allows for in vitro screening at a 
reasonably large scale [110], but it is constrained by the fact that the proliferative capacity of the 
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cultures dissipates over time. To overcome these limitations, three-dimensional organotypic or 
‘organoid’ long-term culture methods have been developed that combine the experimental flexibility 
of “immortalized” in vitro systems with the tissue context of animal studies [111]. For colon, normal 
organoids containing only epithelial cells can be derived by culturing primary nontransformed 
intestinal tissue in Matrigel – a gelatinous mixture made of laminin-rich extracellular matrix and 
growth factors – supplemented with additional growth factors that mimic the intestinal niche [112, 
113] (Figure 3). CRC organoids require less stringent combinations of niche factors than normal 
intestinal organoids [114, 115].  
 
Patient-derived normal and CRC organoids have been leveraged to advance cancer modeling and 
decompose mechanisms of CRC tumorigenesis. Using CRISPR/Cas9-based genome editing, Matano 
et al. sequentially introduced loss-of-function mutations of APC, SMAD4 and TP53 and gain-of-
function mutations of KRAS and/or PIK3CA in normal human colon organoids, followed by growth 
selection under customized cell culture conditions [116]. Organoids engineered to express all five 
mutations formed small, highly differentiated tumors with limited local infiltration after implantation 
under the kidney subcapsule in mice, and were unable to metastasize to the liver after injection into the 
spleen. Conversely, organoids from patients’ advanced tumors that had accumulated spontaneous 
oncogenic mutations during their evolutionary history displayed robust renal subcapsular growth and 
produced prominent spleen-to-liver dissemination [116] (Figure 3). These results suggest that the 
ectopic introduction of canonical driver mutations in normal human intestinal cells results in incipient 
tumor formation but is not sufficient for a CRC tumor to manifest an invasive and metastatic 
phenotype. Additional lesions that drive full-blown CRC malignancy may be fueled by epigenetic 
modifications and CIN; indeed, the engineered organoids largely lacked karyotypic or DNA 
methylation aberrations, which were instead abundantly present in patient-derived CRC organoids 
[116]. The acquisition of gene copy number alterations after genetic manipulation of normal intestinal 
organoids appears to be influenced by experimental variables; for example, different from Matano et 
al., Drost et al. found that combined loss of APC and TP53 in normal human colon organoids was 
sufficient for the appearance of CIN and massive aneuploidy [117]. In patient-derived CRC organoids, 
a combination of genetic lineage tracing and ablation systems revealed robust functional plasticity. 
LGR5+ cells were shown to act as cancer stem cells that constantly fueled tumor growth through self-
renewal and at the same time were able to morph into differentiated post-mitotic cells. Selective 
ablation of LGR5+ cells transiently regressed tumors; however, this shrinkage was followed by tumor 
regrowth due to the replenishment of the LGR5+ pool by differentiated cells that had reacquired stem-
like features [118]. 
 
Clonal organoids derived from isolated cells can be considered as proxies for the single cells from 
which they originate (Figure 3). Phylogenetic trees constructed through deep genomic analysis of CRC 
clonal organoids revealed that driver mutations commonly found in CRC (such as those in APC, 
KRAS, and TP53) were present in all organoids, that is, they were trunk mutations common to all cells 
of the original tumor. However, many ‘private’ mutations could be detected in the distal branches of 
the phylogenetic trees, indicating that they had arisen later during tumor progression and had 
contributed to tumor genetic diversification [119]. These results are in line with the ‘big bang’ model 
of CRC tumorigenesis, according to which genetic variants that confer selective advantages occur 
early in a cancer’s evolution and are followed by the neutral expansion of genetically different but 
equally fit subclones [120, 121]. Stable alterations of DNA methylation and transcriptome states were 
also observed in cloncal organoids, with phylogenetic topologies similar to the mutation-based trees 
(Figure 3). Conversely, response to drugs commonly used in CRC was variable – especially with 
chemotherapeutic agents – and not linked to the geographical location of the organoid-initiating cells 
in the original tumor or the genetic distance between clones [119]. Similar to that observed in PDX-
based lineage tracking experiments [93], these results suggest that diversification in biological 
behavior has no evident correlation with the extent of mutational diversification. 
 
The application of organoid technology in systematic high-throughput drug screens to validate 
clinically relevant response biomarkers and nominate new ones is rapidly expanding (Figure 3). A 
seminal study with a library of 83 compounds tested in 19 CRC organoids confirmed the association 
between KRAS mutations and lack of response to EGFR blockade as well as general refractoriness of 
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BRAF-mutant tumors to BRAF inhibitors, as observed in the clinic [114]. This effort also identified 
loss-of-function mutations in RNF43, resulting in cell hypersensitivity to secreted WNT factors, as 
predictive biomarkers of CRC susceptibility to neutralization of autocrine/paracrine activation of the 
WNT pathway [114]. CRC organoids have also been shown to recapitulate the clinical response of the 
donor patient to cetuximab, regorafenib, and TAS-102 [122]. Interestingly, organoids derived from a 
patient with regorafenib-sensitive liver metastases proved to be resistant to the drug when cultured ex 
vivo as isolated cancer cells; however, liver orthotopic xenografts developed from the same organoids 
coopted the host’s blood vessels and displayed reduced vascularity after regorafenib administration, in 
keeping with the assumption that response to regorafenib is mainly driven by its antiangiogenic 
activity [122]. A concordance between organoid viability and patient response was also found in the 
case of irinotecan monotherapy and FOLFIRI, but not when FOLFOX was used [123]. Possibly, 
stromal and immune components absent in organoid cultures tune sensitivity to oxaliplatin more than 
they do with other drugs, or reliable response to oxaliplatin requires tailored culture conditions that are 
less stringent for other chemotherapeutics. Finally, organoids derived from rectal cancer have been 
demonstrated to predict clinical and histopathologic responses to neoadjuvant chemoradiation, as 
observed in matched donor patients [124, 125]. 
 
 
Challenges and emerging opportunities 
 
The utilization of living biobanks of tumor samples holds considerable promise for in vivo and in vitro 
interrogation of clinically actionable pathways and for the study of tumor evolution. But the use of 
patient-derived models should be accompanied by careful appreciation of their real potential not only 
as platforms for biomarker validation and target discovery but also as reliable proxies of the biological 
and molecular fingerprints of matched tumors in donor patients. A critical knowledge of the accuracy 
of patient-derived models in retaining the characteristics of original tumors is crucial for assessing 
their ability to predict drug activity in the clinic. 
 
Preservation of genomic architecture in propagated tumor-derived models 
An ongoing debate revolves around the question whether serially passaged PDXs and long-cultured 
organoids preserve the genomic makeup, in terms of copy number alterations (CNAs), of their pre-
derivation counterparts. Using gene expression microarray data to infer large-scale CNA profiles, Ben-
David et al. reported extensive copy number divergence between the pre-implantation tumor of origin 
and the corresponding xenograft at the first in vivo passage, which was exacerbated along serial 
propagations [126]. This raised concerns that mouse-specific selective pressures may “artificially” 
influence PDX tumor evolution, with implications for the ability of PDXs to faithfully model patient 
treatment response. However, expression-based CNA calling only enables assessment of aberrations at 
the gross scale of chromosomal arms. Recently, a joint effort of the National Cancer Institute PDXNet 
consortium and the EurOPDX consortium produced a DNA-based enumeration of copy number 
profiles at high segmental resolution in a large collection of PDX models [127; Woo et al., Nat.Genet., 
accepted in principle]. This analysis did not confirm systematic copy number deviation between 
patient tumors and PDXs; rather, it documented high CNA retention during PDX engraftment and 
passaging (both globally and at the level of cancer-related genes) for many tumor types including 
CRC. Notably, CNA variations between pre-implantation and xenografted tumors were comparable to 
differences in multi-region samples of tumors in patients, indicating that the impact of PDX-associated 
CNA drift is similar to the natural intratumoral evolution that occurs in patients.  
 
Somatic mutations, typically assessed by whole exome sequencing, are largely concordant between 
original tumors and matched PDXs, even though evolutionary neutral subclonal alterations may arise 
at low allele frequency during PDX propagation [128]. In CRC, mutations in known oncogenic drivers 
are retained in PDXs when present in matched patient tumors and do not appear de novo in mouse-
passaged tumors [84]. An overall preservation of CNA and mutational landscape, with the caveat that 
the number of samples analyzed so far is limited, has also been observed in CRC organoids as 
compared with the corresponding patient tumors [84, 114, 129]. However, CIN CRC organoids tend to 
tolerate mitotic errors, which results in the accrual of chromosome mis-segregations over time [130]. 
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Similarly, an accumulation of synonymous and nonsynonymous mutations has been noted during 
prolonged culturing of MSI CRC organoids [115]. 
 
The hurdles of co-clinical trials 
If patient-derived models are high-fidelity “avatars” of pre-derivation tumor samples, they could be 
used – in principle – for real-time assessment of drug sensitivity, which may be reverse-exploited to 
guide treatment decisions in donor patients. Co-clinical trials have been proposed in which PDX mice 
are treated with panels of drugs – either agents with broad-brush anticancer activity or targeted 
compounds based on molecular predictors; then, when a positive signal for a specific therapy emerges, 
the information is transferred back to the donor patient for clinical evaluation [81, 131]. While 
intriguing, an approach of this kind requires that therapeutic outcomes be univocally deciphered and 
rigorously interpreted. For example, spurious positive signals may arise for treatments that delay 
tumor growth, resulting in tumors that are smaller than untreated controls at end point, but larger than 
they were at treatment initiation. This information may be indicative of biological sensitivity (i.e., the 
drug reduces cancer cell proliferation) but has little clinical relevance; indeed, in patients, a lesion that 
enlarges during treatment (even to a relatively small extent) denotes tumor progression, and the 
therapy is usually discontinued due to lack of efficacy.  
 
Another issue with the execution of PDX-based co-clinical trials is the need to cope with quick 
turnarounds. Results in mice must be promptly returned to donor patients to inform treatment 
decisions. However, research with PDXs notoriously implies long-term and time-consuming 
experiments. “Cutting corners” in the name of rapidity, for example by reducing the number of 
animals tested in each treatment cohort, would lead to insufficiently powered studies and scientifically 
unreliable conclusions. Compared with PDXs, organoids are expected to speed up the bench-to-
bedside pipeline due to their higher manageability. However, we are still missing metrics that 
adequately capture how and to what extent organoids deliver a clear prediction of the outcome in 
patients. There is no consensus on the adoption of common readouts of drug sensitivity (reduction of 
cell proliferation versus induction of apoptosis) and shared methodologies for data acquisition (digital 
imaging versus cell counts). Moreover, a direct comparison of the concordance between patient-
matched PDXs and organoids in categorizing response or resistance to therapy has not been attempted 
so far on a systematic scale. As always when dealing with resource platforms, standardized guidelines 
built on cumulative experience will be a prerequisite for direct transfer of preclinical results to 
patients. 
 
Integration of the tumor immune microenvironment: humanized mice and co-cultures 
The necessity of using immunocompromised mice to prevent xenograft rejection hampers the use of 
conventional PDX models to assess the efficacy of immunotherapies. Humanized mice are 
immunodeficient animals in which the human immune system is partially reconstituted by introducing 
CD34+ hematopoietic stem cells (HSCs), peripheral blood mononuclear cells (PBMCs), or tumor-
infiltrating lymphocytes (TILs) [6, 132] (Figure 4). Attempts to generate humanized CRC models have 
been scant. Cell-line xenografts in mice engrafted with allogeneic or autologous human PBMCs 
showed delayed growth kinetics and increased infiltration of cytotoxic T cells after treatment with a 
combination of nivolumab and urelumab, a CD137 agonist monoclonal antibody that enhances T‐cell 
and natural killer‐cell antitumor activity [133]. Similar results were observed in a dMMR/MSI-H PDX 
model, but not in a microsatellite stable model, after humanization with cord blood-derived CD34+ 
cells and treatment with nivolumab [134].  
 
Although humanized mice appear to recapitulate some of the effects of immunotherapy observed in 
patients, the procedure of mouse humanization is afflicted with several drawbacks. PBMC and TIL 
infusion typically causes severe graft-versus-host disease starting 2-5 weeks after injection [135, 136], 
which restricts the investigative window to temporal limits that are hardy compatible with 
experimental needs. Transplantation of HSCs results in a more complete hematopoietic reconstitution, 
but their maturation as well as the effector functions of their differentiated progeny are compromised 
by the lack of cytokines, phagocytes, and HLA molecules of human origin in the mouse host. The 
application of genome editing technologies for mouse genetic engineering is expected to increase the 




Another emerging asset to reconstruct the functional interactions between cancer cells and the immune 
microenvironment relies on hybrid organ-on-a-chip platforms, which allow the build-up of more 
complex multicellular systems [137]. Reductionist methodologies involve the initial establishment of 
separate cultures of epithelial organoids and immune cells, followed by artificial reconstitution in co-
mingling experiments. This approach has been used to set up co-cultures of cancer cells from primary 
or metastatic CRC with high mutational burden and autologous PBMCs, wherein cancer cell organoids 
triggered antigen-specific stimulation of tumor-reactive cytotoxic T cells in the PBMC fraction [138] 
(Figure 4). More sophisticated air-liquid interface (ALI) methods have also been deployed that enable 
the en bloc preservation of the tumor epithelium and its endogenous immune stroma, including 
fibroblasts, tumor-associated macrophages, T and B lymphocytes, and natural killer cells [139]. ALI 
cohesive units propagated from CRC biopsies retained the T cell receptor heterogeneity of the T cells 
present in original tumors and modeled the effects of nivolumab by recapitulating cytotoxic T cell 
expansion and antibody-dependent tumor cytotoxicity [139] (Figure 4). Assessing the functional 
consequences of immune checkpoint blockade using organoid technology is poised to complement 
existing descriptive biomarkers, such as neoantigen load, in the identification of patient-specific 





The clinical and experimental observations discussed above illustrate the power of population-level 
studies – both in patients and in the preclinical setting – to credential candidate predictive biomarkers 
and identify novel determinants of therapeutic response as well as novel targets. Recent evidence also 
highlights the value of patient-derived xenografts and organoids as tools to investigate subclonal 
dynamics during tumor evolution and functional heterogeneity under drug pressure. The credibility of 
patient-derived models in preserving the molecular architecture of the corresponding pre-derivation 
tumors is now supported by large-scale analytical efforts and the use of accurate genomic approaches. 
These merits notwithstanding, several issues remain, which are mostly related to the inability of PDXs 
and organoids to recapitulate heterotypic interactions between cancer cells, stromal cells, and immune 
cells. Mouse humanization procedures and co-culture assays are expected to aid the development of 
more holistic models that incorporate immune components. However, the impact of bone marrow 
reconstitution (let alone that of PBMC or TIL infusion) on the quality, quantity and topographical 
localization of immune infiltrates in transplanted tumors is difficult to assess, as is the influence of the 
host on the differentiation trajectories and functionality of transplanted human HSCs. Likewise, 
cocultures of cancer cell organoids with endogenous, syngeneic immune cells fail to mimic the 
subtleties of the tumor microenvironment in terms of complexity, representation, and reciprocal 
distribution of immune components. Another dimension of complexity is the difficulty – if not the 
impossibility – of replacing stromal elements such as endothelial cells and fibroblasts with their 
human counterparts; hence, the limitation remains that mouse-derived cytokines and growth factors in 
some cases do not crossreact with receptors that are expressed by human cancer cells. 
 
A careful appraisal of the (vast) extent of information that can be reliably garnered by the use of 
patient-derived models, but also a clear understanding of their shortcomings, will be key to deliver 
robust, predictive and translationally relevant knowledge. This critical attitude will help triage and 
move to the clinic only those findings that emerge from conclusive and generalizable preclinical 
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LEGENDS TO FIGURES 
 
Figure 1: Application of colorectal cancer PDXs in translational research. PDX trials are 
conducted in parallel with or after clinical trials to “reverse validate” response biomarkers and 
genotype-response associations identified in patients (left panel). Cells dissociated from PDXs can be 
genetically manipulated and used in lineage tracing experiments to assess the temporal and spatial 
dynamics of functionally heterogeneous clones under drug pressure (middle panel). Genomic analysis 
of large-scale PDX collections enables the discovery of molecularly defined CRC subpopulations, 
which can be tested for the presence of potential therapeutic targets through pharmacologic 
experiments in vivo (right panel). 
 
Figure 2: Application of genetically modified animal models of colorectal cancer in translational 
research. Genetically modified mice carrying targeted gene recombination of common mutations 
(Apc, Kras, Tgfbr2 and Trp53) in intestinal stem cells develop immune-cold CRC tumors with high 
levels of stromal TGF-; blockade of TGF- signals prompts the recruitment of immune effector cells 
into the tumor microenvironment and sensitizes tumors to immunotherapy (left panel). Another mouse 
model develops metastatic CRC featuring a pronounced stromal reaction due to targeted expression of 
active Kras and Notch and loss of Trp53 in villin-positive intestinal cells; Notch-dependent production 
of TGF- by cancer cells promotes tumor infiltration by neutrophils and metastatic dissemination, 
which can be blunted by inhibition of neutrophil recruitment or TGF- signaling (right panel). 
 
Figure 3: Application of CRC organoids in translation research. Patient-derived organoids from 
normal colon can be engineered to express drivers of colorectal tumorigenesis, alone and in 
combination; this approach allows to explore the contribution of each driver to tumor onset and 
progression and helps understand how and to what extent engineered organoid models recapitulate the 
biological characteristics of spontaneous tumors from patients (left panel). Mutational profiles, 
methylomics and/or RNA sequencing analysis of clonal organoids derived from individual cells of 
patients’ tumors can be used to reconstruct phylogenetic trees and investigate CRC tumor evolution 
(middle panel). Organoids can be exploited in mid- to high-throughput drug screens, and results from 
pharmacologic analyses can be coupled with molecular profiles to extract associations between drug 
sensitivity and specific molecular traits (right panels). 
 
Figure 4: Incorporating the immune system into patient-derived models. The immune system of 
immunocompromised mice can be partially reconstituted with different approaches of variable 
efficacy, from infusions of PBMCs or TILs to transplantation of HSCs derived from the bone marrow 
or umbilical cord blood; once humanized, mice can be xenografted with patient-derived tumors and 
treated with immunotherapy to assess tumor growth kinetics and intratumor representation of immune 
cells before and after treatment (left panel). Cocultures of immune cells and cancer cells can be 
performed by co-mingling tumor organoids and autologous PBMCs or by implementing ALI methods 
that allow the preservation of the tumor epithelium and the associated immune stroma in cohesive 
units; both approaches are permissive for expansion of tumor-specific cytotoxic T cells (right panel). 
Table 1. Validated and proposed biomarkers of response to existing therapies in colorectal cancer 
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Oxaliplatin  ERCC1 (Resp) YES NO 33, 34 
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Anti-angiogenic therapy     
Bevacizumab 
 VEGF-A, VEGF-D, HGF, 
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ER-associated genes (Resp) 
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Other targeted therapies     
Trastuzumab + 
pertuzumab/lapatinib 
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85, 97 
Entrectinib, ponatinib 
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Pembrolizumab/nivolumab 
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Resp, response; Resist, resistance; Tox, toxicity 
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